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Abstract
A number of groups have been investigated as potential protecting groups for the 
thiol functionality of cysteine residues during Solid Phase Peptide Synthesis. Of 
these the 4-picolyl system has been found to be successful. A short, efficient 
synthesis to the protected amino acid and mild cleavage conditions have been 
developed. This protected amino acid has been applied in the synthesis of a number 
of interesting cysteine-containing peptide fragments.
Deglycosylated human erythropoietin (dhEPO) has been synthesised by SPPS, 
employing the picolyl group for cysteine protection. Purification of this material has 
been achieved by gel filtration. The synthetic material has been characterised by 
amino acid analysis, SDS-PAGE, isoelectric focusing and N-terminal sequencing.
Attempts have been made to synthesise deglycosylated human erythropoietin via a 
fragment coupling technique. All fragments were successfully synthesised and 
purified and model ligation studies carried out.
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E. coli Escherichia coli
EDT ethanedimiol
EPO erythropoietin
EPObp erythropoietin binding protein
dhEPO deglycosylated human erythropoietin
rhEPO recombinant human erythropoietin
Abbreviations
uhEPO urinary human erythropoietin
EDTA ethylenediaminetetraacetic acid
EDT ethanedithiol
ES-MS electrospray mass spectrometry
ET-1 endothelin-1
FAB fast atom bombardment
Fmoc 9-fluorenylmethoxycarbonyl
FPLC fast protein liquid chromatography
GRH growth hormone
HF hydrogen fluoride
HIV human immunodeficiency virus
HO At l-hydroxy-7-azabenzotriazole
HOBt 1-hydroxybenzotriazole
HOCt ethyl-1 -hydroxy- \H- 1,2,3 -triazole-4-carboxylate
HPLC high performance liquid chromatography











NMR nuclear magnetic resonance
/NOC isonicotinyloxycarbonyl
PAGE polyacrylamide gel electrophoresis
PAM hydroxymethylphenylacetamodimethyl
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl












SASRIN super acid sensitive resin
SCD catalytic domain of stromelysin
SDS sodium dodecyl sulfonate
S'Bu tertiary butyl sulfenyl
SPOS solid phase organic synthesis
SPPS solid phase peptide synthesis
t triplet
TAEC transfer active ester condensation
Tbfmoc tetrabenzojtf, c,g, j]fluorenyl-17-methoxycarbonyl
TBTU 2-( 1 H-benzotriazole-1 -yl)-1,1,3,3 -tetramethyl
	uroniumtetrafluoroborate 
TFA trifluoroacetic acid 
TFMSA trifluoromethanesulfonic acid 
TIS triisopropylsilane 
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Introduction to Solid Phase Peptide Synthesis
1.1 Background
Peptides and proteins are primary metabolites found in all living cells. They are 
responsible for the maintenance and function of both the human and animal body and 
are the principal materials of skin, muscle, tendons, nerves, blood, enzymes, 
antibodies and many hormones. The word protein is derived from the Greek 
proteios, meaning first, indicating the importance with which these molecules were 
ranked even before their true purpose and function could be investigated.
The potential therapeutic use of these natural compounds is huge and already a 
number of peptides are manufactured on a kilogram scale for clinical use. For 
example Zoladex, 1 which is manufactured by Zeneca for the treatment of breast and 
prostate cancer, and oxytocin, which is often administered during labour. Moreover 
proteins produced by recombinant DNA technology have also been licensed for
••^
medical purposes. Examples here include human erythropoietin, used for the 
treatment of anaemia associated with kidney disease, and interferon-p,3 used in the 
treatment of multiple sclerosis. Isolation of peptides and proteins from natural 
sources is possible although yields are often low. Analysis of this material can 
provide the primary sequence of amino acids in the protein backbone. With this 
information there are two routes available to increase the quantity of material 
available. Using recombinant technology the gene, coding for the protein, can be 
cloned and used to express the protein in mammalian cells. Alternatively, a purely 
synthetic route can be adopted to form the linear sequence of amino acids.
A great deal of research has been invested into obtaining proteins via recombinant 
techniques, however, there are drawbacks to this method. Expression levels of the 
protein can be low and, perhaps more seriously, point mutations in the amino acid 
sequence can occur resulting in expression of the wrong material. This problem is
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eliminated in chemical protein synthesis since the chemist has complete control over 
the sequence being synthesised. Single point mutations can have disastrous effects. 
For example, when a glutamate residue in haemoglobin is substituted for valine 
sticky patches develop on the protein surface, causing red blood cells to adopt the 
'sickle' shape characteristic of the disease sickle cell anemia (Figure 1.1). 4 As a 
result transportation of red blood cells around the body is hindered leading to a 
potentially fatal condition.
Structure of (ickle-cell haemoglobin
Normal red blood cell Formation of sickled red blood cell Sickled red blood cell
Figure 1.1 Mutation Leading to Sickle Cell Anemia
1.2 Peptide Synthesis
The chemical synthesis of peptides has been a challenge addressed for many years. 
The laborious task of solution phase peptide synthesis can be highlighted with the 
synthesis of oxytocin,5'6 for which Du Vigneaud received the Nobel Prize in 1955. 
Although the synthesis of such a small peptide may appear trivial, the unambiguous 
formation of a dipeptide from two different amino acids requires careful 
consideration of the likely impurities. There are four possible products from this 
reaction, as outlined in Figure 1.2. Also, there is the risk of unwanted side reactions 
occurring at the side chain functional groups of the amino acids.
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Figure 1.2 Products from Uncontrolled Dipeptide Synthesis
By blocking the carboxy group of one amino acid and the amino group of the second, 
activation of the free carboxy group enables directed formation of the peptide bond. 
Protection of any side chain functional groups prevents side reactions occurring. It is 
this protecting group strategy which forms the basis of contemporary peptide 
synthesis.
1.3 Solid Phase Peptide Synthesis
Merrifield7 revolutionised peptide synthesis with the introduction of solid phase 
peptide synthesis (SPPS), a fact recognised with the award of the Nobel Prize for
o ^^
chemistry in 1984. The basic concept of SPPS is outlined in Figure 1.3. It involves 
anchoring the first TV" protected amino acid to an insoluble solid support via a 
covalent bond. Cleavage of the A^ protecting group and subsequent coupling of the 
next amino acid can be repeated in a stepwise manner, generating the desired peptide 
sequence. Excess reagents are used to drive the reactions to completion and then 
simply washed away from the solid support. On completion of the synthesis the 
peptide is simply cleaved from the solid support and purified. Thus the rigorous 
purification of each intermediate peptide required via conventional solution phase 
















Repeat to generate 
desired sequence
ProtR2 H O
Cleavage from solid support 
and side chain deprotection
O R 1
OH
Figure 1.3 General Outline ofSPPS
1.4 The Solid Support
The novel concept introduced by Merrifield was that of the solid support. If an 
insoluble polymer could be developed to swell in organic solvents a solvated gel 
would be produced. Reagents could then penetrate within the matrix of this gel 
enabling reactions to take place. By using excess reagents, the reactions could be 
driven to completion. Obviously the resin would need to possess a sufficiently rigid 
structure to enable the excess reagents to be removed by a simple filtration step. 
Functionalisation of the resin would facilitate covalent attachment of the first 
residue. With the increasing length of the syntheses, the stability of the resin was 
also crucial, considering the number of chemical steps to which it would be exposed.
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Merrifield investigated a number of polymeric supports and found the best to be a 
copolymer of styrene crosslinked with 1% divinylbenzene (Figure 1.4). 7 Swelling of
the resin was observed in DCM and DMF.
ci
ci 
Figure 1.4 Polystyrene Crosslinked with 1 % Divinyl Benzene
Although this support is still widely used in SPPS a number of others have been 
proposed. The most notable of these are the polyacrylamide resins developed by 
Sheppard and co-workers (Figure 1.5). 9' 10' 11 These are much less hydrophobic than 
the polystyrene based resins and resemble the polarity of the growing polypeptide 
chain. As a result, both the resin and the peptide chain are solvated. This appears to 
help in the synthesis of peptides which tend to aggregate on the polystyrene supports. 
These resins are compatible with both Fmoc and Boc methodology, which will be 





Figure 1.5 Polyacrylamide Resin
Tentagel®12 and PEGA 13 resins have been developed for use in SPPS. PEGA swells
extensively in a range of organic solvents and is freely permeable to macromolecules 
of up to 35 kDa, making it ideal for carrying out on-resin enzyme assays. Tentagel®
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has excellent swelling properties in a number of solvents, including water and 
methanol. Both resins are able to maintain good flow rates in columns, making them 
particularly useful for continuous flow SPPS.
1.5 Linkers
In order to carry out any chemistry on the solid support, the resin must be 
functionalised to enable covalent attachment of the first residue. Modification of the 
C-terminal functionality and the cleavage conditions for the peptide-resin bond can 
be controlled in this way. Merrifield originally chloromethylated the polystyrene 
resin, enabling attachment of the first amino acid as the benzyl ester. 7 The harsh 
acidic conditions required for removal of the N® protecting group, 
benzyloxycarbonyl (Z), did, however, cause slight loss of the peptide from the resin 
through attack of the benzyl ester linkage, Figure 1.6. Obviously this problem 
became more serious with the increasing length of syntheses. Nitration or 
bromination of the resin helped minimise this problem.
RHN
Figure 1.6 Cleavage of the Benzyl Ester Linkage
The introduction of the hydroxymethylphenylacetamidomethyl (PAM) linker 
increased the stability of the anchoring bond. Cleavage is accomplished using 
hydrogen fluoride (HF). 14
The introduction of the base labile 9-fluorenylmethoxycarbonyl (Fmoc) group for N" 
protection, led to the development of linkers which could be cleaved under much 
milder acidic conditions. The alkoxybenzylalcohol (Wang) linker is readily cleaved 
by trifluoroacetic acid (TFA), eliminating the need for HF or
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trifluoromethanesulfonic acid (TFMSA), and has found wide spread use in Fmoc 
SPPS.
Advances in peptide synthesis, combined with the recent explosion of solid phase 
organic synthesis (SPOS), have lead to the introduction of a variety of new linkers, 
which give greater control over the chemistry being performed. The most useful of 
these, which are encountered in SPPS, are outlined in Table 1.1.
Linker Cleavage Conditions of Corresponding Ester
Merrifield Resin7
Original chloromethylated polystyrene resin used by Merrifield. 
Cleavage with HBr in glacial acetic acid.
PAM Resin
Cleavage with HF or TFMSA. 
Resin of choice for Boc SPPS.
Wang Resin
Cleavage with 95 % TFA / water. 
Resin of choice for Fmoc SPPS.
SASRIN Resin
Variant of the Wang linker.
Cleavage occurs under very mild conditions - typically 0.5 - 1 %
TFA in DCM.
Chlorotrityl Resin
Very acid labile - can cleave with 10% Acetic acid / water. 
Useful for the preparation of side chain protected peptide 
fragments.
Rink Amide Resin
Cleavage with dilute TFA generates the peptide amide.
Dibenzosuberone Linker
Cleavage with aqueous TFA.
By varying the nature of the R group can generate a variety of
peptide C-terminal derivatives.
Table 1.1 Common Linkers Encountered in SPPS
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1.6 Protecting Group Strategies
1.6.1 Boc Strategy
Initially Merrifield employed the Z group (1.1) for A^ protection, the problems 
associated with which have been detailed earlier (Section 1.5). In a subsequent 
paper, detailing the synthesis of bradykinin,20 Merrifield employed the more acid 
labile r-butyloxycarbonyl (Boc)21 '22 group (1.2) for TV" protection. Quantitative 
cleavage could be accomplished using milder acids such as TFA, enabling protection 
of the side chain functional groups with the Z group and as benzyl ethers and esters. 
Side chain deprotection and cleavage of the benzyl ester linker could be achieved at 
the end of the synthesis using HF or TFMSA. This work still forms the basis for Boc 
SPPS as carried out today, although there are concerns that the repetitive TFA 
treatment, required to cleave the Boc group, and the final cleavage with HF, may be 








The truly orthogonal approach to SPPS was realised with the development of the 
base labile 9-fluorenylmethoxycarbonyl (Fmoc) group (1.3) by Carpino and Han.23 '24 
This could be used for TV" protection in conjunction with 'Bu derived acid labile side 
chain protecting groups, thus eliminating the use of HF or TFMSA. Cleavage of the 
Fmoc group occurs swiftly with secondary amines such as piperidine. Cleavage of 
the side chain protecting groups and peptide resin linkage can then be achieved using 
TFA. Another advantage encountered with this methodology is that the fulvene - 




OfThis provides a useful means of monitoring the coupling efficiency of each step 
the synthesis. 25 As a result, problematic areas in the synthesis can be identified and 
steps taken to rectify these in any subsequent syntheses.
1.6.3 Side Chain Protecting Groups
Ammo acids contain a variety of side chain functional groups. These require 
protection during SPPS to prevent unwanted side reactions. Ideally these protecting 
groups should be stable to all the conditions employed during SPPS yet be readily 
cleaved at the end of the synthesis. As mentioned above, when the Boc group is used 
for A^ protection, the side chain functional groups can be protected with the Z group, 
benzyl ethers and esters. This approach relies on the greater acid lability of Boc over 
these groups.
With the introduction of the Fmoc group for Na protection, a new approach to side 
chain protection was developed. The base lability of the Fmoc group meant that side 
chain functionality could now be protected with groups which could be cleaved 
under much milder acidic conditions. The most commonly used groups are 
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Table 1.2 Side Chain Protecting Groups Employed in Fmoc SPPS
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Protection of cysteine, arginine, tryptophan and histidine requires more complicated 
methodology. Due to the extremely nucleophilic nature of the guanidino function of 
arginine the Boc group is not sufficient to prevent side reactions at these sites. This 
problem has been addressed with the development of the 2,2,5,7,8- 
pentamethylchroman-6-sulfonyl (Pmc) group (1.5) which can be cleaved with 95% 
TFA in 1 hour. 26 It has been noted, however, that in peptides containing multiple 
arginine residues, the cleavage time must be increased to up to 5 hours to ensure 
complete removal. Slight modification of this group resulted in the development of 
the 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group (1.6) which is 









Histidine is prone to undergo racemisation due to the basicity of the Tt-nitrogen in the 
imidazole ring, which may remove the a-proton producing a planar intermediate. 
Racemisation can be completely eliminated by blocking the 7i-nitrogen with the t- 
butyloxymethyl (Bum) group (1.7). 28 Unfortunately, the multi-step synthesis 
required for production of this group, renders it a financially unviable option. 
Blocking the T-nitrogen with the trityl group (1.8) reduces the bacisity of the n- 
nitrogen, thus suppressing racemisation.
The indole ring of tryptophan does not interfere with peptide bond formation, but 
presents a problem at the cleavage step since it captures electrophiles with great ease. 
As a result, scavengers are essential to sequester the carbocations formed from
10
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cleavage of protecting groups. This problem can be partially addressed with the use 
of competitive scavengers during the cleavage step and also by protection of the 
nitrogen of the indole ring with the Boc group (1.9). 29 Cleavage with TFA generates 
an 7V-carboxy indole (1.10), which is subsequently cleaved under the aqueous 
conditions employed during work up of the peptide (Figure 1.7). This approach is 




Figure 1.7 Protection ofTryptophan with the Boc Group
Cysteine containing peptides often require complicated methodology. This area will 
be reviewed in Chapter 2.
1.7 Peptide Bond Formation
The principal reaction in peptide synthesis is the formation of the amide bond 
between two amino acids. It is essential that this reaction be fast, high yielding and 
free of racemisation. This reaction proceeds most efficiently when the carbonyl 
group is activated, producing a more reactive intermediate. Care must be taken to 
avoid strongly electron withdrawing activating groups since these can induce 
racemisation. Racemisation is base induced occurring via an oxazolone intermediate 
(Figure 1.8). Urethane derived protecting groups such as Boc and Fmoc help 
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Figure 1.8 Racemisation via the oxazolone intermediate
1.7.1 Carbodiimides
Dicyclohexylcarbodiimide (DCC) (1.11) was introduced as an activating agent for
"3 O
the formation of amide bonds in 1955. Merrifield demonstrated the synthetic utility
_ _ i~i
of DCC as an activating agent in SPPS in his original paper. 
Diisopropylcarbodiimide (DIC) (1.12)33 has now become the reagent of choice in 
SPPS. This is simply due to the enhanced solubility of the A^JV'-diisopropylurea by- 
product in the solvents used in SPPS, enabling easier separation from the solid 
support.
Carbodiimides react with the free carboxyl group of an amino acid forming an O- 
acyl urea (1.13). This can then go on to react in one of three ways (Figure 1.9);
1. React directly with the free amino function to generate the peptide bond 
(1.14)
2. Form a symmetrical anhydride (1.15) from reaction with a second 
equivalent of the amino acid.
3. React with another oxygen nucleophile to form a more stable intermediate 











As mentioned above, symmetrical anhydrides are formed when the (9-acyl urea 
reacts with a second equivalent of the amino acid. These reagents have found great 
utility in peptide synthesis, due to their ease of preparation and excellent acylating 
properties. There is, however, a drawback since two equivalents of the amino acid 
are required. Half of the amino acid is then essentially wasted and so this becomes a 
very expensive method of peptide bond formation.
1.7.3 Active Esters
The potential of active esters was first noted in 1964 when/7-nitrophenol esters were 
coupled under modified SPPS conditions. 34 1-Hydroxybenzotriazole (HOBt) (1.17) 
was introduced as a co-reagent with carbodiimide to prevent racemisation and 7V-acyl 
urea formation. 35 The success achieved by this method resulted in the preparation of 
analogues of HOBt in an attempt to improve on coupling efficiency. Both 1- 
hydroxy-7-azabenzotriazole (HOAt) (1.18)36 and ethyl-l-hydroxy-lH-l,2,3-triazole- 















HOCt has been applied successfully in the stepwise synthesis of the large proteins 
EPO38, IFN-y39'40 and MMP-341 , which were unobtainable using HOBt mediated 
coupling. More favourably, the unwanted side reaction, causing irreversible nitrile 
formation of the side chain of asparagine and glutamine residues (Figure 1.10),42 
















Figure 1.10 Dehydration of the Asparagine Side-chain
Extensive racemisation studies have been carried on HOCt mediated couplings. Of 
the twenty naturally occurring amino acids, only histidine was shown to racemise, a 
problem encountered with a number of activating agents. This could be reduced to a 
negligible level with the introduction of a three fold molar excess of HOCt. 43
1.8 Advances in Peptide Synthesis
Changes in methodology are required in order to access large proteins of greater than 
200 residues. Unless each step in SPPS is 100% efficient, there is a limit to which 
the methodology can stretch. By breaking a protein into smaller peptide fragments 
(typically 50 amino acids), it can be envisioned that these could then be readily 
synthesised and purified. Ligation of these smaller fragments could then generate the 
desired sequence.
It is nearly 100 years since the azide method for peptide bond formation was 
introduced by Curtius. 44 This methodology was adapted by Hirschmann to 
synthesise ribonuclease A, a 104 residue protein, via fragment coupling. 45
14
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Recently Kent has introduced a new method called native chemical ligation.46 The 
initial work involved the reaction of a C-terminal a-thiocarboxylate on one fragment 
with a TV-terminal a-bromoacyl moiety of a second fragment. The resultant ligated 
material having a thioester bond at the ligation site. The mild acidic conditions 
required to carry out the reactions render all side chain functional groups on the 
protein backbone non-nucleophilic, thus side chain protection is not required. The 
methodology has since been extended to generate a natural amide bond at the ligation 
site. Here a C-terminal a-thioester is reacted with an ^/-terminal cysteine residue, 
generating the thioester intermediate (1.20), which then undergoes spontaneous 
rearrangement to give the native amide bond and the free thiol side chain of the 
cysteine residue (Figure 1.11). Further modification of this work means that it is no 
longer limited to A^-terminal cysteine residues.48
Figure 1.11 General Outline of Native Chemical Ligation
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Once the linear sequence of amino acids has been formed, a peptide or protein must 
fold into its biologically active form before it can produce any effect in vivo or in 
vitro. Secondary structure forms with the development of a-helices, p-sheets and p- 
turns, through hydrogen bonding and ionic and hydrophobic interactions between the 
side chains of the amino acids. However, it is the development of tertiary structure 
which defines the total three-dimensional conformation of the polypeptide chain. 
The thiol side chains of cysteine residues play a key role in the development of this 
tertiary structure, since the oxidative linking of two cysteine residues generates a 
disulflde.
As mentioned previously, it is necessary to temporarily mask the side chain 
functionality of amino acids during SPPS, to prevent side reactions occurring at these 
sites. Cysteine is no exception to this rule, the reactivity of the thiol side chain 
necessitating its protection. Indeed, it can be argued that purification of chemically 
synthesised peptides containing cysteine can be simplified if the thiol remains 
protected during this process.
2.2 Orthogonal Protecting Groups and Disulflde Formation
In proteins and peptides containing two cysteine residues, disulflde bond formation 
can be carried out quite simply by S-deprotection followed by oxidation. Peptides or 
proteins containing two or more disulflde bridges require more complicated 
methodology since the S-S bond formation must be directed to produce the correctly 
folded material. Essentially there are three approaches to this problem;
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1. Subject the fully deprotected material to folding conditions and identify 
the correct material via comparison with a standard or by structural 
analysis.
2. Coupling of fragments with pre-formed disulfide bridges. This method is 
highly sequence dependant.
3. Directed disulfide formation through the use of orthogonal cysteine
protecting groups.
Of these methods the use of orthogonal protecting groups is possibly the most 
effective. For this reason a number of protecting groups have been proposed for 
cysteine residues in SPPS. These will be reviewed in Section 2.3.
Traditionally, disulfide formation is carried out by air oxidation at neutral or basic 
pH in aqueous media. 1 '2 '3 '4 This is a very slow method and generally requires a high 
dilution of the peptide or protein to be effective. Similarly, the thiol-disulflde 
interchange reaction, with reduced and oxidised glutathiones, is also time consuming 
and requires high dilution conditions. 5 Despite these drawbacks the long reaction 
time results in the production of the thermodynamically preferred confomer, which is 
advantageous when forming two or more disulfldes.
Stronger oxidising agents such as iodine and potassium ferricyanide (K3Fe(CN)6) can
(-\ 7 Rbe employed in the formation of a single disulfide. '' However, methionine, 
tyrosine, tryptophan and histidine are susceptible to undergo side reactions under 
these conditions.9 As a result, the concentration of oxidising agent used must be kept 
to a minimum and the reaction carried out cautiously.
Tarn10 has detailed a procedure that can be used over a wide pH range and at high 
concentration to effect disulfide formation. Dimethylsulfoxide (DMSO) is used as a 
mild oxidant generating water and dimethylsulfide as harmless, easily separable, by- 
products. An optimum concentration of 20% DMSO by volume, in a variety of 
solutions, effects complete disulfide formation in peptides in 0.5 to 4 hours. Studies 
have shown that only methionine is prone to undergo oxidation, sulfoxide formation 
being observed when working at a pH of less than 3.
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2.3 Current Cysteme Protecting Groups
The soft nucleophilic nature of the thiol group facilitates selective S protection by 
direct alkylation of cysteine. Several protecting groups have been proposed for 
cysteine. Table 2.1 details those which have been investigated for use in conjunction 
with Fmoc methodology.
Protecting Group Cleavage Conditions
Sodium in liquid ammonia.
Benzyl 11,12
/-Butyl 13
Thallium (IE) acetate, causes side reaction with Trp. 
Mercuric acetate, 15 causes Met oxidation to sulfoxide. 
Both reagents present toxicity problems.
Ph
T -. ,16,17 Tntyl
Complete cleavage with 95% v/v TFA/H2O 
Deprotection with iodine produces the disulfide in one 
step.6 Possible side reaction with Trp residues.9
Acetamidomethyl (Acm) 18
Mercuric acetate at pH 4. Silver trifluoromethane 
sulfonate (AgOTf), 19 thallium (III) acetate, 14 iodine20 
and TFMSA-DMSO-TFA21 have all been reported.
Thiols and phosphines effect complete cleavage before 




PdCl2(PPh3)2 mediated cleavage with Bu3 SnH and 
AcOH. AcOH required to prevent formation of allyl 
thio ether. Partial cleavage is observed in TFA.




3% TFA in DCM-Triethylsilane (95 - 5) in 30 mins. 
Cleavage can be accomplished with the peptide still 
bound to the resin.
25Methoxy trityl
Table 2.1 Fmoc Compatible Cysteine Protecting Groups
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2.4 Problems Encountered with Cysteine Residues in SPPS
Perhaps the most serious problem encountered with cysteine residues is racemisation, 
due to the acidity of the a-proton. It has been reported that Fmoc-Cys(Trt)-OH may 
undergo considerable levels of racemisation when 2-(lH-benzotriazole-l-yl)-l,l,3,3- 
tetramethyluroniumtetrafluoroborate (TBTU), HOBt and DIEA mediated activation 
and coupling is employed.26 Coupling via the neutral pre-formed symmetrical 
anhydride yielded material with no detectable level of epimerization. Thus, it can be 
concluded that the epimerization occurs via a base induced mechanism. Extensive 
racemisation studies have been carried out using the superior coupling reagent
9*7
HOCt. No racemisation of Fmoc-Cys(Trt)-OH has been observed under these 
conditions.
Peptides containing C-terminal cysteine are also prone to undergo an undesired side
^o
reaction when treated with piperidine. During routine cleavage of the Fmoc group, 
the piperidine may also attack the a-proton of the C-terminal cysteine residue. This 
results in elimination generating a dehydroalanine derivative (2.1). A second 
molecule of piperidine then attacks the alkene, producing a piperidine adduct (2.2).
FmocHN
(2.2)
Figure 2.1 Piperidine Attack of C-Terminal Cysteine Residues
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Attempts were made to eliminate this reaction using the bulky non-nucleophilic base 
l,8-diazobicyclo[5.4.0]undec-7-ene (DBU). However, the dehydroalanine derivative 
was still isolated from the reaction. No method has yet been developed to 
completely eliminate this undesired reaction. Residues protected with either the 
triryl or Acm group were found to be susceptible to this reaction, although the 
problem is more pertinent for Acm protected residues. Only C-terminal cysteine 
residues undergo this reaction - any other cysteine residues in the peptide chain 
remain untouched.
2.5 Pseudo Prolines
During peptide synthesis formation of secondary structure is often paralleled by a 
significant decrease in the solubility of the peptide chain. As a result the resin 
effectively shrinks, leading to poor accessibility of reagents and, an often substantial, 
decrease in coupling efficiency. Incorporation of a proline residue into a potentially 
secondary structure forming region disrupts the formation of helices and (3-sheets, 
thus the solubility of the peptide chain and coupling kinetics are improved.29
Mutter and co-workers have introduced structure-disrupting agents, known as pseudo 
prolines (Wro), to circumvent this problem in SPPS. 30'31 Condensation of serine, 
threonine or cysteine residues with an aldehyde or ketone yields an oxazolidine or 
thiazolidine ring. These exhibit structure disrupting properties comparable to proline 
residues when incorporated into peptide chains.
SH
Figure 2.2 Thiazolidine Formation from Condensation of Cysteine and a Ketone
The cyclic system prefers to form a cis-amide bond with the subsequent residue, 




rS^Ki _xvkl O N c N
H R2
Pseudo Praline
/ \ H Cleavage fl
R^/N/ ° 
R! SH
Figure 2.3 Kink Formed in Peptide Chain
By cleaving the oxazolidine or thiazolidine ring at the end of the synthesis, the parent 
amino acid can be regenerated. Thus, pseudo prolines also serve as a temporary side 
chain-protecting group for the hydroxyl group of serine and threonine and the thiol 
group of cysteine.
By varying the nature of the C-2 substituents the chemical stability of the ring can be 
altered. This can be seen in the following cysteine protected derivatives.
MeyS^i ^Sfl
le' N^C02H hf (AC09HMe pj ^C02  H N- ^ 02  H H" -Co2H
——————Y——————
TFA Labile TFA Stable 
Figure 2.4 Stability of Thiazolidine Derivatives
2.6 Outline of Research
It would be desirable to develop an acid and base stable protecting group for the thiol 
functionality of cysteine residues which could readily be removed in a subsequent 
chemical step. Thus an orthogonal protecting group to those already described 
(Table 2.1) could be synthesised and employed for the synthesis of peptides and 
proteins containing two or more disulfides. Ideally, such a protecting group should 
avoid the use of toxic reagents in cleavage, such as the thallium and mercuric salts 
required for the cleavage of the Acm and ^-Bu groups. 14 ' 15 ' 18
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The general requirements for a protecting group can be outlined as follows:
1. Suppress the intrinsic reactivity of the amino acid side chain.
2. Not introduce any new and undesirable reactivity.
3. Be completely stable to the reaction conditions of both acylation and 
deprotection steps.
4. Ultimately be removable under mild conditions, which do not damage the 
polypeptide chain.
It was proposed that introduction of a pyridine ring into the pseudo proline system 
would generate a group stable to both acidic and basic conditions. Cleavage would 
then be facilitated under reductive conditions. The thiazolidines shown below were 
both proposed as potential cysteine protecting groups.
(2.4)
Figure 2.5 Proposed Cysteine Protecting Groups
2.7 Pseudo Proline Derived Cysteine Protecting Groups
2.7.1 Synthesis of the Protecting Groups
Both these compounds were readily synthesised from condensation of L-cysteine 
with the corresponding pyridine carboxaldehyde, using the procedure of Fulop and





2N NaOH, EtOH 
room temp, 2hrs
Figure 2.6 Synthesis of the Protecting Groups
Both compounds were obtained as a mixture of diastereomers, due to the 
introduction of the new chiral centre at C-2. Initial attempts to separate these proved 
unsuccessful since it can be seen that the diastereomers interconvert freely in 
solution (Figure 2.7). 34'35 Although undesirable, the chirality of the amino acid itself 
is not affected and the protecting group will be removed in a subsequent step.
N N
H C02H —— PJ® C02H p| C02H
Figure 2.7 Interconversion ofPseudo Prolines in Solution
Coupling of amino acid derivatives to a growing peptide chain containing an A/- 
terminal pseudo proline generally results in low yields. This is due to the decreased 
nucleophilicity of the ring nitrogen of the oxazolidine/thiazolidine. 31 This problem 
can be overcome by coupling a pre-formed dipeptide of the form Fmoc-Xaa-Wro- 
OH. These dipeptides can readily be incorporated into the growing peptide chain 
using standard coupling techniques. Racemisation is not found to be a problem due 
to the proline like structure of the C-terminal residue.
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2.7.2 Attempted Cleavage of the Protecting Group 
2.7.2.1 3-Pyridyl Isomer
Cleavage of the protecting group was attempted using sodium cyanoborohydride 
(NaBH3CN) in aqueous acetic acid. NaBH3CN is known to be a selective reducing 
agent for the production of 1,4-dihydropyridines. 36'37'38 If this intermediate could be 
generated, then it was thought likely that the protecting group would cleave via the 
mechanism outlined in Figure 2.8.





Figure 2.8 Proposed Cleavage of the 3-Pyridine Protecting Group
Analysis of the product produced indicated that only one of the thiazolidine ring 
bonds had cleaved, namely the C-S bond as indicated in Figure 2.8. The enamine 
intermediate (2.5) did not undergo attack by the hydroxyl ion as expected, but rather 
rearranged to form the more stable aromatic system (2.6). Consequently cleavage of 
the C-N bond was not observed. Attempts were made to drive this reaction to 
completion by introducing an excess of reducing agent, however complete cleavage 
of the system was not observed.
2.7.2.2 4-Pyridyl Isomer
Cleavage of the 4-pyridine isomer was attempted using activated zinc dust as the 
reducing agent. 39 This method has successfully been employed for the cleavage of 
the isonicotinyloxycarbonyl (/NOC) group, which can be used for protection of the g- 





Figure 2.9 Lysine Protected with the Isonicotinyloxycarbonyl Group
However, the product of the reaction was again the partially cleaved material.
The described results show that the pyridine ring does provide an acid and base 
stable protecting group for the thiol functionality of cysteine residues. The 
somewhat disappointing results for cleavage of this group do, however, indicate that 
partial cleavage of the system is possible. Since this implies that reduction of the 
aromatic system is occurring under these conditions, it should be possible to use 
these results in the development of a modified protecting group.
2.8 Picolyl Thioethers
Picolyl thioethers of the form outlined below (Figure 2.10) should fulfil the 
requirements for the protecting group. The pyridine ring again providing the acid 
and base stability. From the results obtained with the thiazolidines reductive 
conditions should facilitate cleavage of the C-Sbond.
(2-7) (2.8)
Figure 2.10 Picolyl Thioethers as Potential Cysteine Protecting Groups
S-4-Picolyl-Z-cysteine (2.8) has previously been reported as a protected derivative 
for SPPS by Young and co- workers,41 who have demonstrated that quantitative 
cleavage can be accomplished by electrolytic reduction. Despite the obvious 




A further advantage of these picolyl thioethers is that the amino group of the cysteine 
can be protected with the Fmoc group, allowing incorporation of the protected amino 
acid into peptide chains using conventional coupling procedures.
2.8.1 Synthesis of the Protecting Group
Synthesis of both the 3-picolyl (2.9) and 4-picolyl (2.10), Fmoc protected, amino 
acid can be readily accomplished in two steps, as outlined below, Figure 2.11.
/SH










Figure 2.11 Synthesis of Fmoc-Cys(Pic)-OH
2.8.2 Preparation of a Test Peptide
To establish if Fmoc-Cys(Pic)-OH could be utilised in automated SPPS a test peptide 
was synthesised, namely the C-terminus of the vasoconstrictor Endothelin-1 (ET-1).
YlFlClHlLlDll II IWh-NH2HO2C-
Figure 2.12 Sequence of Test Peptide
Using standard procedures both isomers were found to couple in greater than 99% 
efficiency. Both peptides were subjected to acidiolytic cleavage and purified by 
semi-preparative HPLC. Amino acid analysis (AAA) indicated the picolyl group is 
stable to prolonged acid treatment. The protected amino acid was found to elute
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intact from the ion exchange column with retention properties similar to histidine. 
This provides a useful means of analysis for picolyl containing peptides.
2.8.3 Attempted Cleavage of the Protecting Groups
2.8.3.1 ^-S-Picolyl-JL-Cysteine (2.11)
Cleavage of the 3-picolyl group was attempted using the NaBH3CN conditions 
employed for the pseudo proline cleavage. Unfortunately, no cleavage of the 
protecting group was observed. This was a somewhat surprising result, since partial 
cleavage of the thiazolidine was observed under identical conditions.
Electrochemical studies on S-3-picolyl-Z-cysteine indicate that the reduction of the 
pyridine ring does indeed take place. However, the reduction is rapidly reversible, 
therefore, it appears likely that the 1,4-dihydropyridine is formed, but spontaneously 
re-aromatises before cleavage of the system can occur.
2.8.3.2 S^-Picolyl-l-Cysteine (2.12)
Cleavage was attempted using the established conditions of zinc dust in aqueous 
acetic acid. The reaction was monitored by HPLC and it can be seen that the peak 
corresponding to the protected peptide, with retention time 16.4 minutes, started to 
disappear and a new peak appeared, with retention time 17.8 minutes, indicating that 
cleavage of the protecting group was successful.
Deprotected peptide 
RI 17.8mins -
 \'-; ~ r~~FlH"=r
Time
Figure 2.13 HPLC Trace Showing Cleavage of Picolyl Group
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A mass of 1210.36 was observed by MALDI-ToF mass spectrometry, corresponding 
to the deprotected peptide. A positive Ellmans' Test, which detects free thiols, 
confirmed that cleavage of the picolyl group had indeed occurred.
Electrochemical studies on this material indicated that the reduced form of this 
isomer was sufficiently stable to allow the cleavage to proceed to completion.
2.8.4 Racemisation Study
The 4-picolyl group fulfilled the initial requirements for a cysteine protecting group. 
However, as mentioned previously, racemisation is an undesired side reaction 
observed for a number of protected cysteine derivatives. In order to establish if 
racemisation occurred, using this protected cysteine derivative, the tri-peptide H^N- 
Ala-Cys(Pic)-Gly-OH (2.13) was synthesised using HOCt mediated coupling. 
Racemisation of the cysteine residue can be identified by *H NMR spectroscopy, 
since the characteristic doublet of the methyl group of the alanine residue will
27
resonate as two characteristic doublets at ~1.3ppm.
As can be seen from the JH NMR spectrum (Figure 2.14), there is no detectable 
level of racemisation of the cysteine residue. A sample of the peptide was prepared 
with the D-Cys(Pic) residue and used to spike the *H NMR sample. This confirmed 
that it was possible to identify diastereomers using this technique.
AJ
Figure 2.14 *HNMR Spectrum ofAla-Cys(Pic)-Gfy
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2.9 Application to Synthesis 
2.9.1 Oxytocin
In order to demonstrate the synthetic utility of Fmoc-Cys(Pic)-OH in SPPS the 
synthesis of oxytocin was undertaken. Oxytocin is a nine residue peptide containing 
two cysteine residues. This would enable oxidation to be attempted, to ensure that 
the picolyl group does not introduce any features, which would later impair disulfide 
bond formation.
HO.C
Figure 2.15 Linear Sequence of Oxytocin
Oxytocin was synthesised using standard SPPS techniques, all amino acids were 
single coupled as the active HOCt ester. No drop in coupling efficiency was seen at 








Figure 2.16 Fmoc Deprotection Profile of Oxytocin
Cleavage of the picolyl protecting groups was achieved using zinc dust, complete 





Figure 2.17 HPLC of Oxytocin a) Before and b) After Picolyl Group Cleavage
Disulfide formation was attempted using 20% v/v DMSO in TFA. Monitoring of the 
reaction by HPLC gave a good indication of the progress of the disulfide formation. 
After 4 hours the S-S formation was deemed complete and the folded material was 
isolated by semi-preparative HPLC.
All products were analysed by amino acid analysis and electrospray mass 













Aspj (1.03), Gluj (1.08), Glyi (1.03), Ilei (0.97) 
Leuj (1.04), Tyrj (0.83), Pro! (1.03)
AsPl (0.87), GlUl (1.07), GlYl (1.28), Cys2 (0.86), 
Ilei (1.03), LeUl (1.39), Tyri (1.08), PrOl (1.53)
AsPl (0.97), GlUl (1.04), GlYl (1.01), Cys2 (0.35), 
lid (0.96), Leu! (1.03), Tyr! (0.98), Prd (1.00)
Table 2.2 Results for Oxytocin Synthesis
2.9.2 Endothelin-1
The endothelins are a family of peptides, which have potent and well characterised 
effects on the cardiovascular system. 42 Of these endothelin-1 (ET-1) is the major 
isoform, derived from the precursor Big ET-1. It is thought that the endothelins may
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also have a role in the central nervous system acting as neurotransmitters.43 ET-1 in 
particular is involved in the regulation of conditions associated with vasoconstriction, 
for example hypertension, chronic heart failure and renal failure.44'45
Figure 2.18 Linear Sequence of ET-1
Endothelin-1 (ET-1) is a 21 residue peptide containing two disulfide bridges. 
Therefore, it provided an interesting target to study the orthogonality of the picolyl 
group in conjunction with the triryl group. The trityl group is acid labile, cleaving 
during treatment of the peptide-resin with TFA. Thus it should be possible to form 
the disulfide from the two free thiol groups generated at this stage. Cleavage of the 
picolyl groups will then liberate the remaining thiols, which can then be oxidised to 
produce the unambiguously folded material.
From the deprotection profile it can be seen that the synthesis appeared to suffer a 
substantial drop, however despite repeating the synthesis with double coupling cycles 






5 20 \ 
0
» * » *
Residue 
Figure 2.19 Deprotection Profile of ET-1 with 2 Picolyl Groups
Purification of the material was achieved with the introduction of the 
tetrabenzo[tf,c,g,/]fluorenyl-17-methoxycarbonyl (Tbfmoc) moiety at the TV-terminus 
of the peptide. This group has been developed to facilitate separation of truncated 
sequences from the desired material.46 By exploiting the high affinity of this planar
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aromatic moiety for charcoal, sequences containing the Tbfhioc group can be 
adsorbed onto the charcoal.47'48 Material labelled with the Tbfmoc group is readily 
identified since the group has a characteristic absorbance at 364nm. Truncates and 
any other non-labelled impurities can be washed away leaving the pure peptide 
bound to the charcoal. Cleavage of the Tbfmoc group from the peptide can then be 
























Figure 2.20 General Outline of Tbfmoc Affinity Purification
Following purification of ET-1, disulfide formation was effected using DMSO 
mediated oxidation. However, upon subsequent treatment of the peptide with zinc 
dust to effect picolyl group cleavage, it appeared that the disulfide bond already 
formed was also undergoing cleavage. This perhaps should not have been totally 
unexpected, considering the reducing conditions used to cleave the picolyl group.
A sample of commercially available L-cystine was subjected to the picolyl group 
cleavage conditions. Analysis of the product produced from the reaction proved that 











Figure 2.22 Reduction ofL-Cystine
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Although this was a disappointing result, it did prove that the picolyl group is 
compatible with the Tbfmoc affinity purification method for synthetic peptides. In 
order to demonstrate this method fully the synthesis of ET-1 was repeated, this time 
employing picolyl protection for all four cysteine residues. The material was 
purified by Tbfmoc / charcoal affinity purification and the picolyl groups cleaved in 
the manner outlined above. Deprotection appeared to be complete after one hour.
Folding of the material was then achieved using DMSO mediated oxidation. 
Although this could generate three possible products, due to mixed disulfide 
formation, only two products were detected by HPLC. The major component 
identified as the correctly oxidised material via co-injection with a commercial 
standard.
ENDOTHELIN ES-MS AMEVO ACID ANALYSIS
Picolyl Protected (2.17) 2859.9 (M*) 
MW 2859.89
Asp2 (2.04), Ser3 (2.20), Ghij (1.25), Va^ (1.25), 
Meti (0.78), Ile2 (1.88), Leu2 (2.20), Tyri (1.10), 
(1.10), His! (1.10), Lysi (0.94)
Deprotected Material (2.18) 2495.1 (M+) 
MW 2495.89
Asp2 (1.77), Ser3 (1.27), GlUl (1.18), Cys4 (0.52), 
Vali (1.18), Met! (0.69), Ilej (2.13), Leu2 (2.10), 
(0.69), Phe! (1.12), His! (1.02), 1^ (1.21)
Folded Material (2.19) 2491.1 
MW 2491.89
Asp2 (2.02), Ser3 (1.96), G!U! (1.19), Cys4 (1.29), 
Vah (1.04), Metj (0.97), Ile2 (1.91), Leu2 (2.07), 
(0.64), Phei (0.97), Hisi (0.98), Lysi (0.96)
Table 2.3 Results for Endothelin-1 Synthesis
2.10 Conclusions
The picolyl group is an effective acid and base stable protecting group for the thiol 
functionality of cysteine residues. Incorporation of picolyl protected cysteine 
residues into growing peptide chains can be readily achieved utilising conventional 
SPPS techniques, HOCt mediated coupling causing no detectable levels of 
racemisation. Unfortunately the reducing conditions required to cleave the picolyl
35
Cysteine Protecting Groups
group do cleave any disulfide bonds already present in the peptide. As a result, the 
picolyl group cannot be employed as an orthogonal protecting group in conjunction 
with the trityl group. However, it is possible that orthogonality could be achieved in 
conjunction with non-acid labile cysteine protecting groups, for example Acm. 
Obviously adopting this approach would necessitate cleavage of the picolyl group 
first. The excess zinc dust can be removed from the peptide, following deprotection, 
simply by filtration. The zinc salts formed during the reaction can be separated from 
the peptide by semi-preparative HPLC or gel filtration. Thus, harmful by-products, 
often accumulated during cleavage of other protecting groups, are avoided.
Additionally, the solubilising effect the picolyl group confers on the peptide chain 
aids in purification procedures. This, coupled with the stability of the picolyl group, 
means that the picolyl group has ideal properties for use in fragment coupling 
reactions using minimally protected peptide fragments. This area will be detailed 
later in Chapter 4.
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SPPS of Deglycosylated Human Erythropoieitin
3.1 Background
Erythropoietin (EPO) is an acidic glycoprotein produced primarily in the kidney of 
adults and the liver of the foetus. It is a member of the extensive cytokine family of
^
proteins, which control a wide range of functions in cells of the lymphoid, 
hemopoietic and reticuloendothelial systems. EPO is found in low concentration in 
the plasma and is responsible for the differentiation of erythroid progenitor cells, 
found in the bone marrow, into mature red blood cells. 4 Red blood cells are required 
for transport of oxygen around the body to various tissues. In cases of hypoxia, EPO 
production, and in turn red blood cell production is increased. Conversely, in cases 
of hyperoxia, a decrease in both EPO and red blood cell production is noted.
The possibility that erythropoiesis was controlled by a hormone was first postulated 
in 1906 by Carnot and Deflandre, 1 although it was 50 years before substantial 
evidence was obtained in support of this. Erslev3 noted an increase in blood 
reticulocytes and hematocrit levels (% red blood cells in blood volume) when 
healthy rabbits were injected with large amounts of plasma from anaemic rabbits.
Isolation of EPO proved to be difficult due to the low concentration of the hormone 
present in the plasma. In 1977 Miyake4 successfully managed to purify a small 
quantity of EPO (uhEPO) to homogeneity from the urine of patients with aplastic 
anaemia. With the advent of modern molecular biology techniques sequencing of 
the protein enabled both Jacobs5 and Lin6 to clone the EPO gene. Expression of this 
gene in either African green monkey kidney cells (COS-1)5 or Chinese hamster ovary 
cells (CHO)6 produced recombinant human erythropoietin (rhEPO). Subsequent 
studies have shown rhEPO and uhEPO to be identical. 7
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Kidney failure can cause a decrease in EPO production resulting in anaemia. 
Treatment of renal failure with blood transfusions can offer temporary relief 
however, transfusions can cause antibodies to develop which can preclude patients 
from later receiving a successful kidney transplant.
Amgen successfully initiated clinical trials of rhEPO in 1985, showing that 
therapeutic doses stimulated consistent increases in patients' hematocrit levels, 
substantially eliminating the requirement for blood transfusions for dialysis patients. 
rhEPO has been clinically licensed as EPOGEN® since 19898 and most patients 
undergoing dialysis receive this as part of their treatment. Since its introduction, 
rhEPO has found application in the treatment of anaemia associated with chronic 
disease, such as rheumatoid arthritis, tuberculosis, cancer and systematic fungal 
infections. 9' 10 OrthoBiotech also distribute rhEPO under the trade name PROCRIT® 
for use in conjunction with Zidovudine (AZT) therapy for the treatment of HIV 
related anaemia.
3.2 Structural Features
The EPO gene encodes a 193 residue pro-protein, comprising of a 27-residue 
hydrophobic signal sequence, which is cleaved during secretion, and the mature 
protein consisting of 166 residues (Figure 3.1).
Ala Pro Pro Arg Leu lie Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu 
Glu Ala Lys Glu Ala Glu Asn He Thr Thr Gly Cys Ala Glu His Cys Ser 
Leu Asn Glu Asn He Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp 
Lys Arg Met Glu Val Gly Gin Gin Ala Val Glu Val Trp Gin Gly Leu Ala 
Leu Leu Ser Glu Ala Val Leu Arg Gly Gin Ala Leu Leu Val Asn Ser Ser 
Gin Pro Trp Glu Pro Leu Gin Leu His Val Asp Lys Ala Val Ser Gly Leu 
Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gin Lys Glu Ala He 
Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr He Thr Ala Asp 
Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu 
Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
Figure 3.1 Sequence ofdhEPO (1-166)
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The physiologically active form of EPO circulating in the plasma is actually des- 
Arg and it appears that this C-terminal processing occurs either intracellularly 
prior to secretion, or during circulation in plasma. 11 EPO contains two 
intramolecular disulfide bonds between Cys2p-Cys55 and Cys7-Cys767 . The small 
disulfide loop between Cys29-Cys5jf is not essential for secretion, 12 although there is a 
marked decrease in activity in its absence, indicating that it appears to be essential 
for correct functioning if the protein. 13
There are three A/-linked sugars at Asp24' 38' 83 and also one O-linked sugar at Ser726 
Glycosylation is not essential for in vitro activity, although it is required for in vivo 
activity. The endoplasmic reticulum lumen is an oxidising environment that 
promotes disulfide formation. Here glycosylation may serve to prevent aggregation 
of the protein and prevent enzymatic degradation from the numerous proteases. 14 
EPO only possesses full biological activity in vivo when it is sufficiently sialylated, 15 
indeed the sialic acid residues account for 40% of the carbohydrate mass. 16 Removal 
of the terminal sialic acid residues from the carbohydrate promotes metabolic 
clearance of the hormone, via binding of the terminal galactose residues to the
17 152
hepatic receptors in the liver. ' Overall, carbohydrates are not required for either 
biological activity or target cell specificity, but serve to prevent premature removal 
of the hormone from the blood stream. 19
The tertiary structure of EPO is proposed to be analogous to that of growth hormone
i^r\
(GRH), which has been crystallised and consists of an anti-parallel four a-helical 
bundle core. It is proposed that EPO consists of four anti-parallel helices with two 
long and one short loop connections. The areas predicted to be oc-helices are highly 
conserved in sequences of EPO from various mammals. 21 Mutations in these areas
1 -^
lead to secretion of protein with little or no activity, indicating their importance in 
the structure and function of the protein.
Recently the NMR structure of an EPO mutant has been solved.22 All glycosylation 
sites were mutated to lysine to aid the solubility of the protein and MK added at the
41
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TV-terminus to increase expression yields in E. coll. Activity was shown to be 
comparable to that of deglycosylated human EPO (dhEPO) expressed in E. coll. The 
structure has been solved as a left handed a-helical bundle with four long helices 
running in an up-up-down-down direction connected by two long cross over loops 
and one short loop (Figure 3.2). Residues comprising the central core have been 
shown to be invariant across the different EPO sequences from various species and 
mutation of any of these core residues has a marked effect on protein folding.
BC loop
AB loop
Figure 3.2 NMR Structure ofMKLysEPO
3.3 Receptor Binding and Activation
EPO excerts its biological effects through the binding to and orientation of two cell 
surface EPO receptors (EPObp), which then trigger an intracellular phosphorylation 
cascade. 23 Cloning and expression of the EPObp gene24 has shown that the receptor 
comprises a single polypeptide chain of 508 residues and apparent MW of 55 kDa. 
EPObp exhibits a number of features common to other members of the cytokine 
receptor family. It contains a single hydrophobic transmembrane domain bearing 
four cysteine residues and a WSXWS motif (where X represents any amino acid) 
close to the transmembrane domain.
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The crystal structure of a soluble EPO mutant (Lys substituted at all three TV-linked 
glycosylation sites) complexed with the receptor has recently been solved (Figure 
3.3). 23
EPO 
EPObp2 K>^ fi^, EPObpl
Figure 3.3 MKLysEPO Complexed with Receptor
22As predicted from the NMR data, the complex is formed as a 2:1 EPObp2 :EPO 
species, where the two receptors are held together through two regions located on 
opposite faces of the EPO molecule. These two interfaces are characterised by a 
high affinity binding at Site 1, and a low affinity binding at Site 2. Site 1 is 
comprised of residues from helices A, B and D along with part of the AB loop. Site 
2 is comprised of residues from helices A and C. Generally the side chain 
interactions at both binding sites are between the positively charged arginine and 
lysine residues of EPO and the negatively charged glutamate and aspartate residues 
ofEPObp.
A comparison of the NMR structure of the isolated protein with the EPObp2 :EPO 
complex reveals that the overall topology and alignment of the a-helical bundle is 
very similar. There are a few differences between the two structures, particularly in 




3.4 Overview of Research
Due to the advances in methodology for SPPS, outlined in Chapter 1, the chemical 
synthesis of proteins of up to 200 amino acids is now a realistic target. Previous 
research has demonstrated this is feasible with the synthesis of EPO,26 interferon-y 
(DSfF-y)27 and the catalytic domain of stromelysin (SCD). 28 Unfortunately, the main 
problem in the chemical synthesis of proteins lies in the subsequent purification 
steps rather than the actual synthesis. The ultimate aim of chemical protein synthesis 
is to achieve a sufficient quantity of material for structural analysis, for example x- 
ray crystallography and NMR spectroscopy. Thus an efficient purification protocol 
must be devised.
3.5 Chemical Synthesis of dhEPO
Synthesis of dhEPO was carried out on a O.lmmol scale using Fmoc-Arg(Pmc) 
functionalised Wang resin. All amino acids were single coupled as the active HOCt 
ester. Previous work indicated that the coupling efficiency can drop substantially at 
the last twenty residues of the synthesis,29 therefore these amino acids were 
introduced via a double couple cycle. The efficiency of the synthesis was monitored 
by measuring the UV absorbance of the fulvene-piperidine adduct (Figure 3.4). 30 
The deprotection profile is used as a diagnostic tool to check that there are no major 
drops in the synthesis, rather than a definitive result of the coupling efficiency.
Arg Lys Phe Ala Arg Asp Val Ala Met Thr Thr Leu 
1 15 29 43 57 71 85 99 113 127 141 155
Residue
Figure 3.4 Fmoc Deprotection Profile of dhEPO
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From the deprotection profile it can be seen that the synthesis appears to have 
proceeded reasonably well, with no significant drops in coupling efficiency. Regions 
where the coupling efficiency appears to be greater than 100% are thought to occur 
due to changes in the swelling properties of the resin, a feature which has been 
observed in the synthesis of other proteins.
On completion of the synthesis a sample of the resin bound protein was characterised 
by amino acid analysis. A series of timed reactions were carried out to determine the 
optimum time for hydrolysis (Table 3.1). The results obtained appeared to be in 
reasonable agreement with the predicted values, suggesting that the synthesis had 




























































































Table 3.1 Amino Acid Analysis of Resin Bound dhEPO
3.5.1 Introduction of the Tbfmoc Group
As detailed for Endothelin-1 (Section 2.9.2), labelling the free TV-terminus of a 
peptide or protein with the Tbfrnoc group provides a useful aid for purification. 
Prior to the introduction of the Tbfmoc moiety, the resin bound Fmoc protected EPO
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was subjected to a further capping cycle, to ensure any free amino groups were 
acylated. Cleavage of the Fmoc group with piperidine enabled introduction of the 
Tbfmoc moiety as the chloroformate.
Cleavage of the protein from the resin and side chain protecting groups was then 
achieved in acidiolytic conditions. Scavengers were added to this solution to mop-up 
carbocations generated from removal of the side chain protecting groups to prevent 
them reattaching to other reactive functional groups in the protein backbone. In 
order to minimise the length of time the protein was subjected to the acid conditions, 
a trial cleavage was carried out on a small sample of resin to determine the optimum 
cleavage time. Samples were removed at hourly intervals and analysed by HPLC. 
Cleavage was observed to be complete after 4 hours.
3.5.2 Tbfmoc Affinity Purification on Charcoal
Affinity purification of the Tbfmoc labelled dhEPO was carried out using charcoal as 
the solid support. After cleavage from the charcoal, the material was passed down a 
Sephadex G-50 gel filtration column to remove the piperidine salts. Initial analysis 
by HPLC indicated that the purification had been successful in removing the non- 
labelled material.
Time Time
(Ay (red) = 214nm, A2 (blue) = 364nm) 
Figure 3.5 HPLC of dhEPO a) before and b) after Tbfmoc Affinity Purification
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Subsequent analysis of the material by SDS-PAGE indicated that, although the 






A B C D
(Lane A, crude Tbfmoc-dhEPO, Lane C dhEPO after affinity purification, Lanes B&D Standards) 
Figure 3.6 SDS-PAGE of Crude and Purified dhEPO
This suggested that low molecular weight material had also been tagged with the 
Tbfmoc group. During the synthesis of the protein, it is possible that the swelling 
properties of the resin change. As a result, some of the free amino groups become 
buried and are temporarily unavailable for coupling. Eventually the swelling of the 
resin again changes and these groups are free to participate in the synthesis. The 
resulting protein has part of the sequence missing and is referred to as a deletion 
sequence.
3.5.3 Conclusions
Although the synthesis of dhEPO appeared initially to be successful, closer analysis 
during purification suggested that a number of deletion sequences had been formed. 
SDS-PAGE proved useful in assessing the overall purity of the material produced. 
Since only a very small quantity of the desired material was observed, it was decided 
not to continue with the purification. During the purification problems were also 
encountered with the solubility of the crude synthetic material, indeed 8M urea did 
not completely solubilise the protein.
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3.6 Synthesis of dhEPO Employing the Picolyl Group for Cysteine Protection
One problem encountered in the purification of dhEPO was the low solubility of the 
protein in a number of solvents. It is known that synthetic proteins containing 
cysteine residues can aggregate due to interactions between the free thiol groups. 31 
Although there is no evidence that this problem had occurred, it was reasonable to 
assume that purification of the protein would be aided if the thiol group remained 
protected at this stage. As a result, synthesis of the protein was repeated using the 
acid and base stable picolyl protecting group for all four cysteine residues. This was 
also expected to aid the solubility of the protein.
Recent research has suggested that the initial loading of the resin is crucial for the 
success of a large synthesis. 32 It has been noted that the synthesis of dhEPO 
proceeds with much greater efficiency when the initial functionality of the resin is no 
greater than 0. Immol/g.
The synthesis of dhEPO(Pic) was carried out on a O.lmmol scale using Fmoc- 
Arg(Pbf) functionalised Wang resin, loaded with an initial functionality of 
O.lmmol/g. From the deprotection profile shown below it can be seen that the 
synthesis appeared to proceed more efficiently, indeed the percentage coupling never 







Arg Leu Thr Gin Ala Leu Trp Asn Ala Glu 
1 18 35 52 69 86 103 120 137 154
Residue 
Figure 3.7 Fmoc Deprotection Profile ofdhEPO(Pic)
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3.6.1 Introduction of the Tbfmoc Moiety
Although used with great success, introduction of the Tbfmoc moiety via the highly 
reactive chloroformate can present some problems. It has been proposed that the 
Tbfmoc moiety may associate with some of the side chain functional groups of the 
peptide or protein. As a result, coupling solely to the free amino group of a peptide 
or protein cannot be guaranteed. Introduction of the Tbfmoc protected derivative of 
the final amino acid should overcome this potential problem. Extensive studies have 
been carried out to develop an efficient route to the synthesis of these N" protected 







Figure 3.8 Synthesis of Tbfnwc-Ala-OH
Coupling of the Tbfmoc protected amino acid is facilitated via the active ester. 
Subsequent cleavage of Tbfmoc-dhEPO(Pic) from the resin and side chain protecting 
groups was achieved under acidiolytic conditions as detailed earlier.
3.6.2 Tbfmoc Affinity Purification on Polystyrene
Purification of Tbfmoc-dhEPO(Pic) was carried out using chromatographic grade 
polystyrene, which has been shown to be a superior support to charcoal. 34 The 
uniform structure of the polystyrene ensures that there are no fine particles and thus a 
pre-washing step can be avoided. The rigid nature of the polystyrene also facilitates 
washing by a simple filtration step.
Once cleaved from the polystyrene-Tbfmoc group, dhEPO(Pic) was desalted by gel 
filtration. Although some purification of the material appeared to have been
49
SPPS of dhErythropoietin
successful, the yield of material recovered after the gel filtration step was less than 
5%. As a result it was felt that this purification step was not applicable for this 
particular protein. It is possible that non-specific absorptions to the polystyrene are 
responsible for this disappointing yield. Such absorptions could occur via the side 
chains of the aromatic amino acids or through hydrophobic interactions with the 
protein and the polystyrene. Since the protein is unlikely to have any defined 
secondary or tertiary structure at this time, it is possible that the hydrophobic amino 
acids are still exposed to solvent rather than buried within the core of the protein.
3.6.3 Sephadex G75 Gel Filtration of dhEPO(Pic)
Size exclusion gel filtration is a powerful tool for the purification of proteins, 
molecules being separated according to size. The gel is composed of a porous 
matrix, which is permeable to small molecules. These become trapped, hindering 
their progress down the column. As the molecules increase in size they are trapped 
to a lesser degree and so pass through the column with little difficulty.
A number of factors affect the efficiency of gel filtration. The length of the column 
is significant since it affects both the retention time of the compound and also the 
degree of resolution. Generally, the volume of the sample load should be less than 
1% of the column volume to ensure maximum resolution. A variety of solvents can 
be used in gel filtration, the main requirements being that they are compatible with 
the chemical structure of the gel medium and that the protein be readily soluble in 
the eluent. 35
Sephadex G-75 Superfine grade was chosen for purification of dhEPO(Pic). 
Sephadex is formed from the cross-linking of dextran and epichlorohydrin and 
displays excellent swelling properties in aqueous media. Sephadex G-75 has a 
fractionation range of 3000-70000 and so is ideal for purification of dhEPO(Pic) 
which has a calculated mass of 18760.14. Greater resolution is obtained with the 
Superfine grade of gel since a slow flow rate is maintained. Previous studies by
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Patterson have shown Sephadex G-75 Superfine grade to be an ideal medium for 
purification of chemically synthesised human interferon-y. 36
DhEPO(Pic) was applied to the column in 6M Urea containing 0.2M NaCl and 0.1M 
phosphate buffer pH 7.5. The protein was then eluted using 20% v/v AcOH/H2O. 
Fractions were collected at hourly intervals and assessed for protein content by UV. 
A sample of all fractions containing protein was removed and lyophilised. SDS- 
PAGE of this material enabled detection of the material containing the protein of 
interest. Generally the first four or five fractions containing protein were found to 
contain dhEPO(Pic) by SDS-PAGE. The efficiency of the column can be seen in the 
SDS-PAGE of the fractions collected.
-0.05
Fraction





10 9 8 7 6
Figure 3.10 SDS-PAGE Analysis ofdhEPO(Pic) After 1st Pass down Gel Column
(Each lane in gel corresponds to a different fraction elutedfrom the gel column)
All dhEPO(Pic) containing fractions were pooled, lyophilised and subjected to a 
further round of size-exclusion gel filtration. The detection and analysis procedure 
detailed above was repeated. From the UV trace of the fractions the emergence of 










Figure 3.11 UVAnalysis ofdhEPO(Pic) After 2nd Pass down Gel Column
(Peak infractions 23 - 28 due to urea elutingfrom column)
This material was again pooled and lyophilised. A final application to the gel 
filtration column generated the pure dhEPO(Pic).
,,^^,^^E^JC-^^^-0.05
Figure 3.12 UVAnalysis of Purified dhEPO(Pic)
3.6.4 Characterisation of dhEPO(Pic) 
3.6.4.1 SDS-PAGE and HPLC
Analysis of the purified protein by SDS-PAGE confirmed the presence of the single 
band material. In common with other synthetic proteins, the band appears to be 
slightly broader than recombinant proteins, although this is possibly due to traces of 
salt still present in the sample.
The HPLC trace confirms the presence of a single component. The broad peak is 
again characteristic of synthetic proteins and possibly accounts for the denatured 











(Lane A Standards, Lane B Purified dhEPO(Pic) 
Figure 3.13 SDS-PAGE and HPLC Trace ofdhEPO(Pic)
3.6.4.2 Tryptic Digest
Since MALDI-ToF analysis on the purified protein was unsuccessful, the protein was 
subjected to enzymatic cleavage and the fragments produced analysed by MALDI- 
ToF mass spectrometry. Trypsin was chosen as the proteolytic enzyme, cleavage 
occurring at the C-termini of lysine and arginine residues. The cleavage was 
complete after two hours. All possible cleavage sites appear to have been cut by the 
enzyme, only 12% of the sequence remaining unidentified by mass spectroscopy. 






















































Tryptic digest was successful in identifying the majority of the polypeptide chain, 
however there was no evidence for the four TV-terminal residues. In order to confirm 
that the synthesis had proceeded to this point a sample of the protein was analysed by 
TV-terminal sequencing. Edman degradation is a powerful technique, which enables 
sequential identification of the amino acids from the TV-terminus. Edman's reagent 
(phenyl isothiocyanate) reacts with the TV-terminal amino acid to produce a 
derivative, which can be released for identification without hydrolysis of the rest of 
the polypeptide chain. Five rounds of Edman degradation were performed 
satisfactorily on dhEPO(Pic), confirming the presence of the TV-terminal sequence of 
the protein.
3.6.4.4 Isoelectric Focusing
The isoelectric point (pi) of a protein is defined as the pH where the individual 
charges of the amino acids cancel out and the net charge is zero. Isoelectric focusing 
(IEF) is a non-denaturing technique, which enables the pi of a protein to be 
determined. By subjecting the protein to an electric current within a pH gradient, it 
will migrate to the point where the net charge is zero. The pH gradient can be 
established by the use of ampholytes. These are small, charged buffer molecules 
which quickly migrate within the cell, establishing a pH gradient increasing from 
anode to cathode.
The protein was loaded into the focusing chamber of the Bio-Rad Rotofor® cell 
along with ampholytes (pH range 3.0 - 10.0). The system was subjected to a 
constant power and the increase in voltage noted over time. Once the voltage 
stabilised, the protein was judged focused at its isoelectric point.
After focusing the individual fractions were harvested and the pH of each measured. 



















































(X denotes fractions not collected)
Table 3.3 IFF ofdhEPO(Pic)
The protein was found in fractions 19 and 20 by HPLC analysis, indicating a pi of 
10.0. The pi of dhEPO has been measured as 8.75,38 therefore it is reasonable to 
assume that introduction of the basic picolyl protecting group on all four cysteine 
residues will cause an increase in the pi of the protein.
3.6.4.5 Amino Acid Analysis
A sample of the protein was hydrolysed in 6N HCI for 24 hours and the amino acid 
composition analysed. The results obtained are in reasonable agreement with the 




















































Table 3.4 Amino Acid Analysis ofdhEPO(Pic) after Purification
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3.6.4.6 Molecular Weight Determination by FPLC
The molecular weight of the synthetic dhEPO(Pic) was analysed by size exclusion 
gel filtration using a Superdex  column. 39 The column was calibrated with a series 
of molecular weight standards (Ribonuclease A, MWt 13700; Chymotrypsinogen A, 
MWt 25000; Ovalbumin, MWt 43000) and the void volume calculated using Dextran 
Blue. Thus, the elution volume parameter KAV can be calculated from the equation;
KAV = (Ve - Vo) / (Vt - Vo)
where Ve is the elution volume, Vo the column void volume and Vt the column bed 
volume. Plotting KAV against log MWt enables calculation of the molecular weight 







4.1 4.2 4.3 4.4 4.5 4.6
Log MWt
4.7
Figure 3.14 Calibration of the Gel Filtration Column
The calculated molecular weight of dhEPO(Pic) is 18.81 kDa. This is in reasonable 
agreement with the expected value of 18.76 kDa.
3.5 Cleavage of the Picolyl Protecting Groups
To be considered a useful method for synthesis and purification of dhEPO, cleavage 
of the picolyl protecting groups must be rapid and quantitative. Previous work with 
oxytocin and endothelin-1 enabled picolyl group cleavage to be monitored by HPLC. 
Unfortunately, the broad HPLC peak of dhEPO(Pic) means that analysis of the 
picolyl group cleavage is unlikely to be possible by this method. Previous work with 
the endothelin system, which also contains four picolyl groups, has shown that 
quantitative cleavage can be accomplished in 1 hour.
56
SPPS of dhErytkropoietin
The protein was subjected to the picolyl group cleavage conditions for 2 hours. The 
time was extended slightly to ensure complete deprotection. Semi-preparative HPLC 
was employed to separate dhEPO from the zinc salts formed during the reaction.
The material obtained from the reaction gave a positive test with Elhnans' Reagent, 
indicating that the material did indeed contain free thiol groups. In order to 
demonstrate that the cleavage had gone to completion a sample of the material was 
subjected to amino acid analysis. As noted in Chapter 2, the picolyl protected 
cysteine is stable to acid hydrolysis, eluting near histidine in the amino acid analysis 







Figure 3.15 Amino Acid Analysis Chromatogram before and after picolyl group
cleavage
3.7 Conclusions and Recommendations
The synthesis and purification of dhEPO(Pic) has been successful. Protection of the 
cysteine residues with the picolyl group aided the solubility and hence the 
purification of the protein. Consistent with previous results, the synthesis of the 
protein was found to proceed with much greater efficiency when an initial resin 
loading of no greater than 0. Immol/g was employed.
A short efficient purification protocol has been described, which should be readily 
amenable to scale up. Cleavage of the picolyl protecting groups presented no 
problems, complete cleavage occurring within 2 hours.
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To cany out any biological assays, the protein must be folded into the biologically 
active form. In nature it is believed that proteins are maintained in a partially folded 
conformation until they reach their final cellular location. Here folding is achieved 
in the presence of specific chaperones or folding catalysts. 40 Molecular chaperones 
such as GroES and GroEL act on the unfolded protein causing release of either the 
fully folded material or a structural intermediate that completes folding after release 
from the cell.41 '42 Proteins containing disulfides require catalytic oxidation by a 
member of the thioredoxin family of enzymes. These include glutaredoxin, PDI, 
DsbA and DsbC.43 '31 Production of these enzymes by recombinant methods should 
enable studies into the folding of the synthetic material. Recombinant dhEPO, 
which was expressed in E. coli, has been successfully folded using copper sulfate
1 o
mediated oxidation. With a combination of the above methods it is likely that 
folding of the synthetic material could be achieved, leading to structural and 
biological activity studies.
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CHAPTER 4
Studies Towards the Convergent Synthesis of dhErythropoietin
4.1 Introduction
Chapter 3 detailed the successful stepwise synthesis and purification of dhEPO. 
However, purification of large proteins obtained by chemical synthesis is hampered 
by the presence of deletion sequences. Deletions may be formed which lack only 
one or two residues. These sequences are likely to be almost impossible to identify 
and even harder to separate from the correct material. One way to overcome this 
problem is to adopt a convergent approach to the synthesis. Thus, a number of 
smaller peptide fragments are synthesised and coupled to generate the desired 
protein. The advantage of this approach being that the synthesis and purification of 
the smaller peptide fragments is simpler than that of the complete protein. Moreover, 
the differences between the ligated material and the individual fragments will be 
more pronounced easing identification and separation of impurities.
As the goals of chemical protein synthesis become ever more ambitious, new 
methodology must be developed. Fragment coupling is perhaps the most promising 
method for accessing proteins of greater than 200 residues. One notable technique is 
that of native chemical ligation developed by Kent and co-workers. 1 '2 '3 This has 
successfully been applied in the synthesis of HIV-1 protease4 and Turkey 
Ovomucoid Third domain. 5 Nevertheless, the traditional method of fragment 
coupling, proceeding via the azide intermediate, seems to offer most scope.
4.2 The Azide Method6 7
Q ___Curtius introduced the azide method in 1902 for peptide bond formation. The 
methyl or ethyl ester of a peptide could be converted into the peptide hydrazide on 
treatment with hydrazine hydrate. Subsequent reaction of this material with an
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organic nitrite produced a reactive azide intermediate, which could undergo coupling 
with the free amino group of another amino acid. Due to the instability of azides 
they are generally not isolated but used immediately in situ. Conversion of peptide 
hydrazides to peptide azides was studied exhaustively by Honzel and Rudinger. 9 
They found the reaction to proceed most efficiently at low temperatures in an aprotic 
organic solvent such as DMF. This remains the most commonly used method for 
conversion of peptide hydrazides to azides.
For many years it was thought that the azide method was completely free of 
racemisation. However, numerous studies have found some degree of racemisation 
results when the peptide azide is exposed to strong bases. 10' 11 ' 12 ' 13 Despite this the 
azide method retains popularity since it presents minimal risk of racemisation in 
optimum conditions. The high reactivity of the azide intermediate requires that 
reactions be carried out at low temperatures. Thus, problems with the solubility of 
the peptide segments are introduced.
4.3 Transfer Active Ester Condensation
Extensive studies have been carried out to find an efficient alternative to the azide 
method. Transfer Active Ester Condensation (TAEC) has been developed from 
modification of the azide method. 14' 15 This method retains all the advantages of the 
azide method whilst eliminating the need for low temperatures and hence the 
associated peptide solubility problems. As in the traditional azide method the 
peptide hydrazide (4.1) is treated with an organic nitrite to form the peptide azide 
(4.2). However, when the reaction is carried out in the presence of a large excess of 
HOCt the peptide azide is trapped in situ to produce the peptide-OCt derivative (4.3), 
Figure 4.1. This derivative can then react with the amino terminus of a second 
peptide fragment to produce the coupled material with a peptide bond at the site of 
union (4.4).
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(4.4)
Figure 4.1 Transfer Active Ester Condensation
Peptide-OCt derivatives are more stable than the corresponding peptide azides with 
greater solubility also observed. Furthermore, due to the acidity of HOCt, addition 
of a mineral acid is not required during the formation of the azide intermediate.
4.4 Outline of Research
It was proposed that the synthesis of dhEPO be repeated using TAEC. The preferred 
coupling sites are at small non-functionalised residues such as glycine, alanine, 
leucine and valine. Analysis of the dhEPO sequence identified four possible ligation 













Pro Arg Leu 
Ala Lys Glu 
Leu Asn Glu 
Trp Lys Arg 
Leu Ala Leu 
Asn Ser Ser 
Val Ser Gly 
Gin Lys Glu 
Arg Thr lie 
Asn Phe Leu 
Thr Gly Asp
He Cys Asp 
Ala Glu Asn 
Asn He Thr 
Met Glu Val 
Leu Ser Glu 
Gin Pro Trp 
Leu Arg Ser 
Ala He Ser 
Thr Ala Asp 










































Figure 4.2 Sequence of dhEPO Potential Ligation Sites Highlighted in Red
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4.5 Hydrazide Versus Semicarbazide Linker
Initial research involved modification of the peptide hydrazide. However, there are 
concerns that, should the azide forming reaction be slow, bis-acyl hydrazine (4.5) 









PEPTIDE f)PEPTIDE 1K "N V1   ) H 8
(4.5)
Figure 4.3 Formation of Bis acyl hydrazine
Employing the less reactive peptide semicarbazide (4.6) as starting material should 
prevent this reaction occuring. Recent research suggests that peptide semicarbazides 
can be efficiently transformed to peptide azides, only requiring a slightly longer 





Figure 4.4 Peptide C-Terndnal Semicarbazide
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Tricyclic amide linker resin (4.7) can be modified to generate the semicarbazide resin 
(4.9). ' Peptides are then synthesised on the resin using standard SPPS protocols, 









Figure 4.5 Synthesis of Semicarbazide Linker
4.6 Protecting Group Strategies
Perhaps the greatest advantage of TAEC is that the majority of side chain functional 
groups do not require protection. Consequently unprotected peptide fragments can 
be ligated, which are inherently more soluble than their protected counterparts. The 
only side chain functional groups which require protection are the thiol functionality 
of cysteine residues and the s-amino group of lysine residues.
The properties of the picolyl protecting group, outlined in Chapter 2, make it ideal 
for cysteine protection. The solublising effect, which the group confers on the 
peptide chain, should also prove advantageous.
Lysine protection is achieved with the 4-methyloxycarbonyl-4-nitro-[2,6-dioxaspiro- 
5,5-undecane] (pTnm) group (4.12). 19 On treatment with acid the acetal of the pTnm 
group cleaves to give the 2,2-bishydroxymethyl-2-nitromethyloxycarbonyl (Tnm) 
group. Cleavage of the Tnm group is readily achieved upon treatment with aqueous
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buffer at pH 8.5. Synthesis of the protected lysine derivative can be achieved as 












Figure 4.6 Synthesis of Fmoc-Lys(pTnm)-OH































Amino Acid Analysis 
(24 hours hydrolysis)
Asp2 (2.1), Thr2 (1.8), Ser, (0.8), Glu4 (4.3), Gly, (1.0), 
Ala3 (3.0), Vah (1.2), Ilei (1.9), Leu4 (4.1), Tyr! (0.8), 
LySl (l.l),Arg3 (3.1),Pro2 (2.0)
Asp4 (3.8), Thr2 (1.8), Serj (0.9), Glu7 (7.4), Gly2 (2.1), 
Ala3 (2.8), Met! (1.1), Ilei (0.9), LeUl (1.0), Tyn (1.0), 
Ph6l (1.1), HiSl (1.0), Lys2 (2.1), Argl (1.1), PrOl (1.4)
Asp2 (2.2), Ser3 (2.7), Glu5 (5.3), Gly2 (2.3), Ala4 (4.1), 
Val4 (4.8), Leu8 (6.5), HiSl (1.2), LySl (1.2), Argl (1.1), 
Pro2 (2.1)
AsPl (1.1), Thr2 (1.7), Ser3 (2.0), Glu2 (2.1), GlYl (1.2), 
Alae (5.9), H6l (1.1), Leu5 (4.9), LySl (1.7), Arg2 (2.4), 
Pr02 i2.2)
Asp3 (3.0), Thr3 (3.7), Serj (1.1), GlUl (1.0), Gly3 (2.6), 
Ala3 (2.6), Val! (1.9), HCl (1.1), Leu5 (5.4), Tyr2 (1.5), 
Phe3 (3.8), Lys3 (3.6), Arge (5.6), PrOl (1.0)
Table 4.1 Results for Synthesis of Fragments for TAEC
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Fragments 2-5 were synthesised on semicarbazide linker resin which was generated 
immediately prior to use. The final alanine residue of Fragment 5 was coupled as the 
Tbfmoc amino acid, Tbfmoc acting as the A^ protecting group during the ligation 
steps and facilitating a final affinity purification step of the protein. Fragment 1 was 
synthesised on Wang resin. All peptides were cleaved under acidiolytic conditions 
and purified by semi-preparative HPLC.
4.8 Attempted Ligation of Fragment 4 and Fragment 5
The ligation of Fragments 4 and 5 was proposed to proceed in an analogous manner 
to that of native chemical ligation.
Cffl___








Figure 4.7 Proposed Ligation of Fragments 5 and 4
Conversion of Fragment 5 to an a-thioether derivative, used in native chemical 
ligation, was deemed not necessary due to the highly reactive nature of the peptide- 
OCt derivative. Conversion of Fragment 5 to its peptide-Oct derivative was 
attempted. However, despite the promising results which indicated that conversion of 
the semicarbazide to the active ester is only marginally slower than that with the 
corresponding hydrazine, 16 the reaction was slow. Even after 24 hours little change 
was noted by HPLC analysis. Attempted ligation of Fragment 4 surprisingly led to 
the disappearance of the 364nm peak, characteristic of the Tbfmoc group, on HPLC,
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indicating that the DIEA was causing some form of decomposition or cleavage of the 
Tbfmoc moiety.
4.8.1 Tbfmoc Cleavage Study
In order to assess the stability of the Tbfmoc group studies were carried out using a 
variety of bases. Tbfmoc-Leu-OH was stirred in a solution of DMF containing the 
base under investigation. An aliquot of the reaction mixture was removed hourly and 




















Table 4.2 Stability of Tbfmoc Group
The stability was taken to be the time after which decomposition of the Tbfmoc 
group was evident by HPLC. From this it can be seen that pyridine is the most 
effective base since the Tbfmoc group appears to be stable for up to 8 hours. 
Accordingly, ligation of Tbfmoc protected fragments should be possible using 
pyridine. Another complementary approach to overcome this problem is 
incorporation of the, DIEA stable, Fmoc group for N" protection.
4.9 Synthesis of Fragment 5A employing the Fmoc Group for TV** Protection
The synthesis of Fragment 5 was repeated employing the Fmoc group for N" 
protection. Recent research has demonstrated that potential bis-acyl hydrazide 
formation from peptide hydrazides is only problematic when working at low 
temperatures. 16 As TAEC avoids the need for low temperatures this competing side 
reaction should not be observed. Synthesis of the peptide was carried out on a 
hydrazide linker, in an effort to enhance the formation of the peptide-OCt derivative.
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4.9.1 Attempted Ligation of Fragment 5A and Fragment 4
Conversion of the peptide-hydrazide to the active ester was attempted under similar 
conditions to those outlined in Section 4.8. After 6 hours there was inconclusive 
evidence by HPLC for the formation of the active ester. Nevertheless, ligation was 
attempted. The peptide component of the reaction was isolated by gel filtration. 
Subsequent analysis of this material by electrospray mass spectrometry indicated that 
both fragments were obtained intact from the reaction. As the peptide hydrazide was 
isolated from the reaction it was assumed that azide formation had not taken place.
4.10 Trial Ligation
Due to the disappointing results obtained in Section 4.9.1, ligation of smaller 
fragments was attempted. If successful, it may be presumed that steric hindrance or 
secondary structure formation may be causing problems in the formation of the 
larger peptide azide intermediate.
Two peptide fragments, both five residues in length (modelling the site of the second 
potential coupling in dhEPO) were synthesised. The N terminal fragment was 
synthesised on the semicarbazide linker resin with the Fmoc group employed for 
protection.
l-l
/—————iJL N NH-, 'BuONO, HOCt _ (—————.1Fmoc—f EVWQGf^N V —————————" Fmoc-[ EVWaGf^OCt






Figure 4.8 Trial Ligation of Small Fragments
Coupling was then attempted using the protocol outlined for the larger fragments.
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Formation of the active ester was observed by HPLC. The reaction was deemed 
complete after 4 hours, although only approximately 80% of the starting material had 
converted to the active ester.
Fragment 4 was added and the reaction left for 1 hour prior to analysis. The coupled 
product was clearly visible by HPLC, subsequent analysis of this material confirmed 
that the coupling had proceeded satisfactorily.
4.11 Conclusions
Coupling of the dhEPO fragments via TAEC, using either the hydrazide or 
semicarbazide peptide derivative, was unsuccessful. Initial studies indicated that the 
Tbfmoc group was not stable to DIEA, prompting a series of studies into the stability 
of Tbfmoc to a variety of bases. Of the bases tested pyridine appeared to offer the 
greatest stability and it is likely that it will prove useful for future work involving 
ligation of Tbfmoc protected material.
Ligation of two smaller peptide fragments has been seen to proceed swiftly using 
TAEC methodology, conversion of the semicarbazide peptide to the peptide-OCt 
derivative posing no particular problems.
Therefore, it appears likely that the problems associated with the larger fragments 
may be due to steric interactions or the formation of some degree of secondary 
structure. As a result the C-terminal functional group may be buried in the core of 
the peptide and therefore, inaccessible to reagents. It is possible that the use of 
structure disrupting agents may help in overcoming such problems. Substituting 
'BuONO with iso-amyl nitrite, which has been shown to be more effective in the 
formation of sterically hindered azides,9 may also prove fruitful.
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All chemicals were purchased from the Aldrich Chemical Company or Fischer 
Acros. Purity was checked by melting point, if solid, and ]H NMR spectroscopy. 
All amino acids were purchased from Bachem, NovaBiochem or PerSeptive 
Biosystems and are of the L configuration unless otherwise stated. Tricyclic amide 
linker resin was purchased from Bachem. p-Alkoxybenzylalcohol (Wang) resin was 
purchased from Bachem or NovaBiochem. Hydrazine resin was purchased from 
NovaBiochem. Peptide synthesis grade dimethylformamide (DMF), 1,4-dioxane and 
piperidine were purchased from Rathburn Chemicals. 7\^V-diisopropylethylamine 
(DIEA) and trifluoroacetic acid (TFA) were peptide synthesis grade and were 
purchased from Applied Biosystems (ABI). Sephadex G-75 and G-50 were 
purchased from Pharmacia.
Melting points were recorded in open capillaries using a Buchi 510 oil immersion 
melting point apparatus and are uncorrected. Analytical thin layer chromatography 
(tic) was performed using plastic sheets precoated with silica gel 60F254 (Merck) in 
the solvent systems indicated in the text. Compounds were visualised by absorption 
at 254nm. Optical rotations were measured on an A1000 polarimeter (Optical 
Activity Ltd) in a 10cm cell in the solvents indicated in the text. Infra red (IR) 
spectra were recorded on a BioRad SPC3200 FT-IR spectrometer. Ultra violet (UV) 
spectra were recorded on a Perkin Elmer single beam spectrometer in the solvents 
indicated in the text. Sonication was carried out at room temperature in a Decon 
F5300b sonic bath. Elemental analyses were performed on a Perkin Elmer 2400 
CHN analyser. Proton NMR spectra were recorded on a Brucker WP-200 (200 
MHz) or a Varian Gemini 2000 (200 MHz) spectrometer in the solvents indicated in 
the text. All chemical shifts were referenced to TMS. All coupling constants (J) are 
quoted in Hz Carbon-13 NMR spectra were recorded on an AC250 (63 MHz)
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spectrometer in the solvents indicated in the text, where q denotes CH3 , t denotes 
CH2, d denotes CH and s denotes quaternary C.
High and low resolution fast atom bombardment mass spectra (FAB-MS) were 
measured on a Kratos MS50TC instrument using thioglycerol, 3-nitrobenzyl alcohol 
or glycerol as a matrix. High and low resolution electron impact mass spectra (EI- 
MS) were recorded on a Kratos 920MS instrument using the matrices described 
previously. Matrix assisted laser desorption ionisation (MALDI) time of flight (ToF) 
mass spectra were recorded on a Perseptive Biosystems Voyager  
Biospectrometry workstation using either a-cyano-4-hydrocinnamic acid or 3,5- 
dimethoxy-4-hydrocinnamic acid as the matrix. Electrospray mass spectra were 
recorded on a Micromass Platform II Mass Spectrometer.
Amino acid analyses (AAA) were performed using a Pharmacia Biotech Biochrom 
20 amino acid analyser or a LKB 4150 alpha amino acid analyser on the hydrosylate 
obtained after heating the sample in 6N HC1 at 110°C in sealed Carius tubes for the 
times indicated in the text. The HC1 was removed on a Savant Speed Vac Plus 
SCI 10A after hydrolysis and the residue reconstituted in 0.2M citrate buffer pH 2.2.
High performance liquid chromatography (HPLC) was carried out using either an 
ABI system comprising 2 x 1406A solvent delivery systems, a 1480 injector/mixer 
and a 1783 detector/controller or a Gilson system comprising 2 x 306 solvent 
delivery systems, a 8lie dynamic mixer, a 805 manomeric module, a 119 UV/vis 
detector and a Gilson 715 gradient controller. Compounds were eluted from the 
various columns described in the text using a linear gradient of acetonitrile (far UV 
grade, Rathburn chemicals) in Milli-Q water with both solvents containing 0.1% 
TFA (HPLC grade, Fisons). All experiments were run on a gradient of 10% - 90% 
MeCN over 30 minutes unless otherwise stated. Columns referred to throughout the 
text for analytical HPLC are Aquapore C± (100 x 4.6mm, 7jum), Aquapore C8 (220 x 
4.6mm, 7jim), Vydac C8 (250 x 4.6mm, 7^im) and Vydac Ci 8 (250 x 4.6mm, 7jim). 
For semi-preparative HPLC the columns employed were Vydac C8 (250 x 10mm, 
lOjim) and Vydac C ]8 (250 x 10mm, lOum).
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5.2 Solid Phase Peptide Synthesis
Automated peptide synthesis was carried out on an ABI 430A synthesiser with on 
line UV monitoring using an ABI 75 8A detector. All peptides were synthesised 
using the 9-fluorenylmethoxycarbonyl (Fmoc) base labile A^ protecting group in 
conjunction with orthogonal acid labile side chain protecting groups and an acid 
labile peptide-resin linker.
5.2.1 C-Terminal Acids
The C-terminal Fmoc amino acid (6 equivalents) was dissolved in the minimum 
amount of DMF and DIG (3 equivalents) added. The solution was sonicated at room 
temperature for 15 mins before being added to Wang resin (Ig) pre-swollen in the 
minimum volume of DMF with a catalytic amount of DMAP. The mixture was 
sonicated at room temperature for 3 hours. The resin was collected by filtration, 
washed with copious quantities of DMF, 1,4-dioxane, DCM, ether and dried.
For a low resin loading (< 0.12 mmol/g) the procedure was modified as follows: 
The C-terminal Fmoc amino acid (3 equivalents) was dissolved in the minimum 
amount of DMF and DIG (1.5 equivalents) added. The solution was sonicated at 
room temperature for 15 mins before being added to Wang resin (Ig) pre-swollen in 
the minimum volume of DMF with a catalytic amount of DMAP. The mixture was 
left to sit on the bench for 50 minutes at room temperature. The resin was collected 
by filtration, washed with copious quantities of DMF, 1,4-dioxane, DCM, ether and 
dried.
5.2.2 C-Terminal Semicarbazides
Synthesis of (2-copolystyrene-l %-divinylbenzene)methyl-aminocarbomethoxy-
5-(9'-fluorenylmethoxycarbonyl)hydrazine-dibenzocycloheptadiene resin (4.10) 1
Modification of the resin
Tricyclic amide linker resin (4.7) (Ig, 0.59 mmol/g) was sonicated in 20% v/v 
piperidine/DMF for 45 mins. The resin was filtered, washed with DMF, 1,4-dioxane, 
DCM, ether and dried.
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Generation of the isocyanate intermediate
The resin was swollen in the minimum amount of DCM and DIEA (102jul,
0.59mmol, leq) added and the mixture sonicated for lOmins. A solution of
triphosgene (0.49g, 1.65mmol, 2.75eq) in DCM (4ml) was added and the mixture
sonicated for a further 20mins. The resin was filtered, washed with DCM, ether and
dried.
FTIR vmax/cm-1 (KBr disc) 2235.9 (N=O=O)
Trapping of the isocyanate intermediate with 9-Fluorenylmethoxycarbonyl 
Hydrazine (4.9)
The isocyanate resin (0.9g) was swollen in the minimum volume of DCM. A 
solution of FmocNHNH2 (4.9) (405mg, 1.59mmol, 3eq) in DCM (5ml) was added 
and the mixture sonicated for 2 hours. The resin was filtered, washed with DMF, 
1,4-dioxane, DCM, ether and dried. A KBr disc of the resin was made to ensure 
complete consumption of the isocyanate species.
5.2.3 Side Chain Protecting Groups
The side chain protecting groups used were as follows: ^-butyl ethers for Ser, Thr and 
Tyr, r-buryl esters for Asp and Glu, ^-butoxycarbonyl (Boc) for Lys and Trp, T- 
triphenylmethyl (Trt) for Asn, Gin and His, 2,2,5,7,8-pentamethylchroman-6- 
sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg 
and Trt or 4-picolyl (Pic) for Cys.
5.2.4 The Fmoc Loading Test
A sample of dry, accurately weighed, Fmoc amino acid resin (3-10mg) was sonicated 
in 20% piperidine in DMF (10ml) for 10 mins at room temperature. The UV 
spectrum of the supernatant was recorded between 320 and 280nm. The resin 
functionality (mmol/g) was then calculated using the Beer-Lambert law (e302 = 
15400 for the fulvene - piperidine adduct).
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5.2.5 The Tbfmoc Loading Test
A sample of dry, accurately weighed, Tbfmoc amino acid resin (3-10mg) was 
sonicated in 20% piperidine in DMF (10ml) for 10 mins at room temperature. The 
UV spectrum of the supernatant was recorded between 380 and 320nm. The resin 
functionality (mmol/g) was then calculated using the equation;
Resin functionality (mmol/g) = (0.613 x Abs364)/weight of resin (mg)
5.2.6 Automated SPPS
Synthetic procedures were programmed into the ABI 430A peptide synthesiser. 
Each synthetic cycle, resulting in the coupling of a single amino acid, involved the 
following steps:
1. Capping
The resin was vortexed with a solution of acetic anhydride (0.5 M), DIEA (0.125 
M) and HOBt (0.2% w/v) in DMF/l,4-dioxane (1:1, 10ml) for lOmins. The 
reaction vessel was then drained and the resin washed 6 times with DMF/1,4- 
dioxane(l:l, 10ml)
2. Deprotection
The resin was vortexed with a solution of 20% (v/v) piperidine in DMF/1,4- 
dioxane (1:1, 10ml) for lOmins. The reaction vessel was drained and an aliquot 
of the solution passed through the UV detector. The resin was then washed 4 
times with DMF/l,4-dioxane (1:1, 10ml), treated with 20% (v/v) piperidine in 




The Fmoc amino acid (1 mmol) was treated with HOCt (1 mmol) and DIC (1
mmol) in DMF/l,4-dioxane (1:1, 8ml) for 15mins to form the active ester which
was then transferred to the reaction vessel
Step 2 Coupling
The mixture was vortexed for 30mins, the reaction vessel drained and the resin
washed 6 times with DMF/l,4-dioxane (1:1,10ml)
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5.3 General Procedure for Cleavage of Peptides from Resin
The resin bound peptide (<lg) was stirred in a scavenger cocktail containing H2O 
(1ml), TIS (0.5ml), thioanisole (0.5ml), EDT (0.25ml) and phenol (750mg) for 10 
minutes. TFA (10ml) was then added to this and the mixture stirred at room 
temperature for the times indicated in the text.
5.4 Ellmans Test2
0.1 - 0.2mg of the compound was dissolved in 6M guanidine.HCl, 0.1M phosphate 
buffer, pH 7.3 and Immol ethylenediaminetetraacetic acid (EDTA) (2ml). lOOfil of 
a 3mM solution of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) in 0.1M phosphate 
buffer, pH 7.3 was added and the solution mixed thoroughly. The rapid appearance 
of a bright yellow colour indicated the presence of a free thiol group.
5.5 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE experiments were carried out using a Bio-Rad Mini-PROTEAN  gel 
electrophoresis apparatus. Proteins were subjected to electrophoresis at 200V 
constant power at 25°C under denaturing conditions using the Laemmli
•^
discontinuous buffer system, and a running buffer prepared with Tris base (9g), 
glycine (43.2g) and SDS (3g) in 600ml deionized H2O (this buffer was diluted 5 fold 
before use). Separating gel (15% acrylamide) was prepared with 1.5M Tris-HCl pH 
8.8 (2.5ml), deionized water (2.35ml), 10% w/v SDS/H2O (lOOjul) and Bio-Rad's 
30% Acrylamide/BIS solutions 37.5:1 mixture (5ml). Stacking gel (4% acrylamide) 
was prepared with 0.5M Tris-HCl pH 6.8 (2.5ml), deionized water (6.1ml), 10% w/v 
SDS/H2O (lOOul) and Bio-Rad's 30% Acrylamide/BIS solutions 37.5:1 mixture 
(1.3ml). Both gels were polymerised with the addition of 10% w/v ammonium 
persulfate (APS)/H2O (lOOjul) and tetramethylethylenediamine (TEMED) (20|ul). 
Protein samples were prepared by heating the sample in the appropriate amount of 
denaturing buffer (deionized H2O (3.8ml), 0.5M Tris-HCl pH 6.8 (1ml), glycerol
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(0.8ml), 10% w/v SDS/H2O (1.6ml), 2-mercaptoethanol (0.4ml) and 1% w/v 
bromophenol blue/H2O (0.4ml)) at 90°C for 5 minutes. All samples were detected by 
staining with 0.1% w/v Coomassie Blue R-250/AcOH:MeOH:H2O (1:4:5) for 1 hour 
followed by destaining in AcOH:MeOH:H2O (1:4:5) until the protein bands could be 
visualised (generally 2 hours).
5.6 Experimental Details
2-(3-pyridinyl)-l,3-thiazolidme-4-carboxylic acid (2.3)
Z-Cysteine (5.76g, 50mmol) and 3-pyridine-carboxaldehyde (4.7ml, 50mmol) were 
heated under reflux in 50% v/v ethanol/H2O (100ml) for 1 hour. The solvent was 
removed under reduced pressure to give a yellow solid which was recrystallised from 
ethanol, affording 2-(3-pyridmyl)-l,3-thiazolidine-4-carboxylic acid as a mixture of 
diastereomers.4 *H NMR spectroscopy indicated a 60 : 40 ratio of diastereomers by 
integration of the epimeric CH. *H NMR (200MHz, d6DMSO 8H/ppm) 5.55 (1H, 
s) = 40%, 5.74 (1H, s) = 60%.
Yield 7.63g, 73%; Mp 159-161°C; CHN found C 51.33%, H 4.85% N 12.85% 
(C9H10N2O2S requires C 51.41%, H 4.79% N 13.31%); MS (El) m/z = 210 (M4); 
HRMS (El) 210.0457 (M* requires 210.0463); *H NMR (200MHz, d6DMSO 
5H/ppm) (* denotes major diastereomer) 3.10 (1H, dd, J = 9.9, 9,6, pH), *3.13 (1H, 
dd, J = 10.3, 4.9, pH), 3.35 (1H, dd, J = 9.9, 6.9, P'H), *3.37 (1H, dd, J = 10.3, 6.8, 
P'H), 3.93 (1H, dd, J = 6.9, 9.9, ctH), *4.21 (1H, dd, J = 4.9, 6.8, oH), 5.55 (1H, s, 
epimeric CH), *5.74 (1H, s, epimeric CH), *7.37 (1H, dt, J = 0.7, 7.8, aromatic H), 
7.39 (1H, dt, J = 0.7, 7.8, aromatic H), *7.84 (1H, dt, J = 7.9, 1.7, aromatic H), 7.98 
(1H, dt, J = 7.9, 1.9, aromatic CH), *8.47 (1H, dd, J - 4.8, 1.7, aromatic H), 8.52 
(1H, dd, J = 4.8, 1.6, aromatic H), *8.62 (1H, d, J = 2.2, aromatic H), 8.69 (1H, d, J = 
2.2, aromatic H); 13C {'H} NMR (63MHz, d6DMSO 8C/ppm) 38.13 (t), 38.34 (t), 
64.93 (d), 65.89 (d), 68.54 (d), 69.12 (d), 123.45 (d), 123.64 (d), 134.76 (d), 135.23 
(d), 148.40 (d), 148.76 (d), 149.44 (d), 135.08 (s), 137.41 (s), 172.05 (s), 172.87 (s); 
(MeOH, g/dm'morW1) 262 (3335); FTIR v^/cnf1 (bromoform) 1137
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(C-O), 1602 (aromatic), 1713 (DO), 2888, 2969 (CH), 3017 (aromatic CH), 3262 
(NH), 3433 (OH); [a]D24 -32.9° (c = 0.46, DMF).
Attempted Cleavage of the Protecting Group
NaBHsCN (375mg, 6mmol, 3eq) was added to a suspension of 2-(3-pyridinyl)-l,3- 
thiazolidine-4-carboxylic acid (2.3) (SOOmg, 2mmol) in AcOH (5ml) at 0°C. H2O 
(20ml) was added to this and the resulting solution allowed to stir at 0°C overnight. 5 
The solvent was removed under reduced pressure to yield a yellow oil. This was 
added to MeCN with stirring, resulting in the precipitation of a white solid, which 
was filtered, washed and dried.
MS (FAB) 213 (MH*); *H NMR (200MHz, D2O, 8H/ppm) 2.91 (1H, dd, J = 5.2, 
14.5, PH), 3.01 (1H, dd, J = 4.9, 14.6, p'H), 3.69 (1H, dd, J - 5.2, 5.0, ocH), 4.15 
(2H, dd, J = 4.6, 13.3, CH2), 7.46 (1H, dd, J = 5.0, 8.0, aromatic H), 7.92 (1H, dt, J = 
8.0, 1.9, aromatic H), 8.50 (1H, dd, J = 1.6, 5.0, aromatic H), 8.54 (1H, d, J - 2.1, 
aromatic H); Ellmans test +ve
2-(4-pyridinyl)-l,3-thiazolidine-4-carboxylic acid (2.4)
Z-Cysteine (5.76g, 50mmol) and 4-pyridine-carboxaldehyde (4.7ml, 50mmol) were 
heated under reflux in 50% v/v ethanol/H2O (100ml) for 1 hour. The solvent was 
removed under reduced pressure to give a yellow solid which was recrystallised from 
ethanol, affording 2-(4-pyridinyl)-l,3-thiazolidine-4-carboxylic acid as a mixture of 
diastereomers.6 !H NMR spectroscopy indicated a 60 : 40 ratio of diastereomers by 
integration of the epimeric CH. *H NMR (200MHz, d6DMSO 8H/ppm) 5.54 (1H, 
s) = 40%, 5.76 (1H, s) = 60%.
Yield 8.54g, 85%; Mp 160-163°C; CHN C 51.16%, H 4.98%, N 12.91% 
(C9HioN2O2 S requires C 51.41%, H 4.79% N 13.31%); MS (FAB) m/z = 211 (MH+), 
HRMS 211.0537 (MH+ requires 211.0541); *H NMR (200MHz, d6DMSO 
5H/ppm) (* denotes major diastereomer) 3.05 (1H, dd, J = 6.8, 8.9, pH), *3.09 (1H, 
dd, J = 6.1, 8.9, PH), *3.31 (1H, dd, J = 6.8, 8.9, P'H), 3.35 (1H, dd, J = 6.8, 6.9, 
p'H), 3.97 (1H, dd, J = 6.9, 8.9, <xH), *4.10 (1H, dd, J = 6.1, 6.8, ocH), 5.54 (1H, s, 
epimeric CH), *5.76 (1H, s, epimeric CH), *7.25 (2H, dd, J = 6.1, 2.9, 2 aromatic 
H), 7.40 (2H, dd, J = 6.1, 2.9, 2 aromatic H), 8.45 (2H, dd, J = 6.1, 2.9, 2 aromatic
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CH), *8.51 (2H, dd, J = 6.1, 2.9, 2 aromatic CH); 13C ^H} NMR (63MHz, 
d6DMSO 5C/ppm) 38.11 (t), 38.30 (t), 65.04 (d), 65.88 (d), 69.27 (d), 69.94 (d), 
121.79 (d), 122.37 (d), 148.54 (d), 149.72 (d), 149.88 (d), 148.83 (s), 151.38 (s), 
151.50 (s), 172.16 (s), 172.74 (s); FTIR v^/cm'1 (bromoform) 1139 (C-O), 1613 
(aromatic), 1716 (C=O), 2889, 2930, 2970 (CH), 3017 (aromatic CH), 3315 (NH), 
3409 (OH); A,max/nm (MeOH, E/drn'moFW1) 260 (3938); [a]D24-34.5° (c = 0.47, 
DMF).
Attempted Cleavage of the Protecting Group
Activated zinc dust (600mg, 9mmol, 4.5eq) was added to a suspension of 2-(4- 
pyridinyl)-l,3-thiazolidine-4-carboxylic acid (2.4) (500mg, 2mmol) in 50% v/v 
AcOH/HiO (20ml). The resulting solution was left to stir for 2 hours at room 
temperature. The excess zinc dust was removed by filtration and the solvent was 
removed under reduced pressure. The resulting white solid was filtered, washed and 
dried.
MS (FAB) 213 (MH+); *H NMR (200MHz, D2O, SH/ppm) 2.87 (1H, dd, J = 4.9, 
11.3, PH), 2.98 (1H, dd, J = 4.8, 11.3, p'H), 3.67 (1H, dd, J = 4.8, 5.0, oH), 4.08 
(2H, s, CH2), 7.31 (2H, dd, J - 6.2, 1.8, 2 aromatic H), 8.49 (2H, dd, J - 6.1, 1.8, 2 
aromatic H); Ellmans test +ve.
<$f-3-Picolyl-Z,-Cysteine (2.7)
3-Picolyl Chloride (HC1 salt) (9.02g, 50mmol) was added to a stirred solution of L- 
cysteine (6.05g, 50mmol) in 2N NaOH (50ml) and ethanol (60ml). After 2 hrs a 
white precipitate formed which was filtered, washed with ethanol, ether and dried in 
vacuo to yield S-3-picolyl-L-cysteine as a white solid.
Yield 9.11g, 86%; Mp. 208-212°C; CHN: found, C 51.31%, H 5.62%, N 13.05% 
(C9Hi2N2O2S requires C 50.92%, H 5.70%, N 13.20%); MS (FAB) m/z = 213 
(MH+); HRMS (FAB) 213.0690 (MH+ requires 213.0698); *H NMR (200MHz, 
D20 8H/ppm) 2.77 (1H, d, J = 6.59, pH), 2.78 (1H, d, J = 4.76, P'H) 3.64 (2H, s, 
picolyl CH2), 3.70 (1H, dd, J = 4.76, 6.59, aCH), 7.24 (1H, dd, J = 4.76, 7.69, 
aromatic CH), 7.69 (1H, dt, J = 7.69, 1.83, aromatic CH), 8.23 (1H, dd, J = 1.47, 
4.76, aromatic CH), 8.31 (1H, d, J - 1.83, aromatic CH); 13C {'H} NMR (63MHz,
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D20 5C/ppm) 31.34 (t), 31.21 (t), 53.31 (d), 134.27 (s), 124.28 (d), 138.01 (d), 
147.40 (d), 148.68 (d), 172.69 (s); FTIR v^/cm'1 (bromoform) 1139 (C-O), 1516 
(aromatic), 1596 (CO), 2118, 2497 (NH2), 2886, 2968 (CH), 3017 (aromatic CH), 
3442 (OH); AWnm (MeOH, e/dm'morW1) 264 (3098); Ellmans test (-ve); 
Crystal Data C9H12N2O2S, M= 212.27, monoclinic, a = 9.934(2), b = 8.777(2), c = 
11.122(3) A, U= 965.7(3) A3 , T= 220(2) K, space groupP21, Z= 4, // = 2.792 mm-
\ 3843 reflections measured, 2328 unique (R^ = 0.0919) which were used in all 
calculations. The final wR(F2) was 0.1359.
^-PicoIyl-L-Cysteine (2.8)
4-Picolyl chloride (HC1 salt) (9.02g, 50mmol) was added to a stirred solution of L- 
cysteine (6.05g, 50mmol) in 2N NaOH (50ml) and ethanol (60ml). After 2 hrs a 
white precipitate formed which was filtered, washed with ethanol, ether and dried in 
vacuo to yield S-4-picolyl-L-cysteine as a white solid.
Yield (9.91g, 93%); Mp. 207-209°C (Lit. 7 209.5-211°C); CHN: found, C 51.30%, H 
5.70%, N 13.37% (C9Hi2N2O2S requires C 50.92%, H 5.70%, N 13.20%); MS 
(FAB) m/z = 213 (MH*); HRMS (FAB) 213.0697 (MH+ requires 213.0698); *H 
NMR (200MHz, D2O 5H/ppm) 2.78 (IH, d, J = 4.76, |3H), 2.80 (IH, d, J = 6.59, 
p'H), 3.64 (2H, s, picolyl CH2), 3.72 (IH, dd, J = 4.76, 6.59, oH), 7.29 (2H, d, J = 
6.26, 2 aromatic H), 8.28 (2H, d, J = 6.26, 2 aromatic H); 13C ^H) NMR (63MHz, 
D2O 8C/ppm) 31.41 (t), 34.02 (t), 53.31 (d), 124.61 (d), 148.67 (d), 148.65 (s)*, 
172.68 (s) * quaternary carbon assigned from low noise decoupled spectrum; FTIR 
Vmax/cnf1 (bromoform) 1140 (C-O), 1527 (aromatic), 1602 (CO), 2123, 2577 
(NH2), 2920 (CH), 3017 (aromatic CH), 3421 (OH); AWnm (MeOH, e/dm3mor 
W1) 260 (6057); Ellmans test (-ve); Crystal Data C9Hi2N2O2 S, M= 212.27, 
triclinic, a = 5.7568(10), b = 8.186(2), c = 11.172(2) A, U= 491.08(15) A3 , T =
293(2) K, space group PI, Z= 2, // = 2.745 mm" 1 , 5316 reflections measured, 3400
_ /\





Fmoc-N-hydroxysuccinimide (4.04g, 12mmol) was added to a stirred solution of 5-3- 
picolyl-L-cysteine (2.7) (2.54g, 12mmol) in 10% Na2CO3/H2O (60ml) and 1,4- 
dioxane (60ml) and allowed to stir at room temperature overnight. The solid N- 
hydroxy succinimide was removed by filtration and the filtrate concentrated to half 
volume, acidified with AcOH and extracted with EtOAc (3 x 150ml). The organic 
extracts were combined, washed with brine (1 x 100ml), dried (Na2SO4) and the 
solvent removed under reduced pressure. The resulting solid was purified by wet 
flash chromatography (CHCl3 :MeOH:AcOH; 85:10:5) to yield TV^-P- 
fluorenylmethoxycarbonyl-S-3-picolyl-L-cysteine as a white solid. 
Yield 3.87g, 74%; Mp. 146-148°C; Tic Rf 0.33 (CHCl3 :MeOH:AcOH; 85:10:5); MS 
(FAB) m/z = 435 (MH+); HRMS (FAB) 435.1397 (MH+ requires 435.1379); *H 
NMR (200MHz, d6DMSO 8H/ppm) 2.69 (IH, dd, J = 13.7, 9.5, (3H), 2.83 (IH, dd, 
J = 13.7, 4.6, p'H), 3.80 (2H, s, picolyl CH2), 4.15 - 4.34 (4H, m, fluorenyl CH, 
CH2, ccH), 7.29 - 7.44 (5H, m, 4 fluorenyl aromatic H, 1 picolyl aromatic H), 7.74 
(2H, d, J = 7.3, fluorenyl aromatic H), 7.81 (IH, d, J = 8.4, picolyl aromatic H), 7.89 
(2H, d, J = 7.3, fluorenyl aromatic H), 8.45 (IH, dd, J = 1.6, 4.8, picolyl aromatic H), 
8.52 (IH, d, J = 1.8, picolyl aromatic H); 13C ^H) NMR (63MHz, d6DMSO 
5C/ppm) 32.34 (t), 46.77 (d), 53.84 (d), 65.92 (t), 120.30 (d), 123.73 (d), 125.46 (d), 
127.26 (d), 136.61 (d), 148.25 (d), 149.96 (d), 123.73 (s), 134.43 (s), 140.89 (s), 
143.95 (s), 156.21 (s), 172.39 (s); FTIR v^/cm"1 (bromoform) 1140 (C-O), 1507 
(aromatic), 1601 (C=O), 1704 (urethane), 2890, 2969 (CH), 3017 (aromatic CH), 
3322 (NH), 3408 (OH); A,max/nm (MeOH, e/dm^norW1) 300 (4883), 289 (4557), 
265 (18120); [ah24 -31.2° (c = 1.1, DMF); Ellmans test (-ve); HPLC (Aquapore 
RP18 C18 A, = 214nm) 50% MeCN, Rt 15min.
7Va-9-Fluorenylmethoxycarbonyl -S^-Picolyl-JL-Cysteine (2.10)
Fmoc-7V-hydroxysuccinimide (4.04g, 12mmol) was added to a stirred solution of 5-4- 
picolyl-L-cysteine (2.8) (2.54g, 12mmol) in 10% Na2CO3/H2O (60ml) and 1,4- 
dioxane (60ml) and allowed to stir at room temperature overnight. The solid N- 
hydroxy succinimide was removed by filtration and the filtrate concentrated to half 
volume, acidified with AcOH and extracted with EtOAc (3 x 150ml). The organic
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extracts were combined, washed with brine (1 x 100ml), dried (Na2SO4) and the 
solvent removed under reduced pressure. The resulting solid was purified by wet 
flash chromatography (CHCl3 :MeOH:AcOH; 85:10:5) to yield tf*-9- 
fluorenylmethoxycarbonyl-S-4-picolyl-L-cysteine as a white solid. 
Yield 3.48g, 67%; Tic Rf 0.33 (CHCl3 :MeOH:AcOH; 85:10:5); Mp. 142-145°C; MS 
(FAB) m/z = 435 (MH+); HRMS (FAB) 435.1371 (MH+ requires 435.1379); *H 
NMR (200MHz, d6DMSO 5H/ppm) 2.72 (1H, dd, J = 9.3, 13.7, pH), 2.86 (1H, dd, 
J = 4.6, 13.7, p'H), 3.77 (2H, s, picolyl CH2), 4.14 - 4.34 (4H, m, fluorenyl CH,CH2, 
aH), 7.28 - 7.43 (6H, m, fluorenyl aromatic H), 7.69 - 7.75 (2H, m, fluorenyl 
aromatic H), 7.87 (2H, d, J = 7.4, picolyl aromatic H), 8.49 (2H, d, J = 5.5, picolyl 
aromatic H); 13C ^H) NMR (63MHz, d6DMSO 8C/ppm) 32.54 (t), 34.27 (t), 46.78 
(d), 53.85 (d), 65.93 (t), 120.27 (d), 125.03 (d), 125.44 (d), 127.25 (d), 127.83 (d), 
148.15 (d), 140.89 (s), 143.94 (s), 150.05 (s), 156.21 (s), 172.28 (s); FTffi v^/cm'1 
(bromoform) 1139 (C-O), 1530 (aromatic), 1611 (C=O), 1686 (urethane), 2890, 
2970 (CH), 3017 (aromatic CH), 3350 (NH), 3466 (OH); ^/nm (MeOH, 
e/dn^mol'W1) 300 (4991), 288 (5859), 265 (17143); [a]D24 -34.0° (c = 0.1, DMF); 
Ellmans test (-ve); HPLC (Aquapore RP18 C18, X = 214nm) 50% MeCN, Rt 15 
min.
Synthesis of HiN-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH incorporating 
Fmoc-5-3-picolyl-L-cysteme(2.11)
The synthesis was carried out on a 0.25mmol starting from Fmoc-Trp(Boc) 
functionalised Wang resin (500mg, 0.51mmol/g). All amino acids were single 
coupled as the active HOCt ester. On completion of the synthesis the resin (730mg) 
was subjected to acidiolytic cleavage for 1 hour. The resin was removed by filtration 
and the peptide precipitated into ice cold ether, centrifuged to a pellet, washed with 
ether (3 x 50ml), dissolved in MeCN/H2O and lyophilised.
Yield 218mg; MS MALDI ToF 1301.29 (Mff, MW 1300.42); HPLC (Hichrom 
Cg/Cig) Rt 20.2mins 63% MeCN; Amino Acid Analysis (24 hour hydrolysis) Aspi 
(1.08), Ile2 (1.91), Leui (1.09), Tyr, (0.79), Phei (0.98), His,(1.14).
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Attempted Cleavage of the picolyl protecting group
Peptide (2.11) (50mg, 0.04mmol) was dissolved in 20% v/v AcOH/H2O (25ml) and 
NaBH3CN (7.5mg, 0.12mmol, 3eq) added. The solution was left to stir at room 
temperature and samples removed for analysis by HPLC at hourly intervals. After 6 
hours there was no change by HPLC and the reaction was left overnight. Analysis 
by HPLC confirmed that only starting material was present.
Synthesis of H2N-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH incorporating 
Fmoc-5r-4-picolyl-Z-cysteine(2.12)
The synthesis was carried out on a 0.25mmol starting from Fmoc-Trp(Boc) 
functionalised Wang resin (400mg, 0.66mmol/g). All amino acids were single 
coupled as the active HOCt ester. On completion of the synthesis the resin (635mg) 
was subjected to acidiolytic cleavage for 1 hour. The resin was removed by filtration 
and the peptide precipitated into ice cold ether, centrifuged to a pellet, washed with 
ether (3 x 50ml), dissolved in MeCN/H2O and lyophilised.
Yield 205mg; MS MALDI ToF 1301.54 (MH+, MW 1300.42); HPLC (Vydac Cw) 
Rt 16.4mins, 53% MeCN; Amino Acid Analysis (24 hour hydrolysis) Aspi (1.14), 
Ile2 (1.46), Leui (1.22), Tyn (0.96), Phd (1.01), Hisi (1.29).
Attempted Cleavage of the picolyl protecting group
Peptide (2.12) (50mg, 0.04mmol) was dissolved in 50% v/v AcOH/H2O (10ml). 
Activated zinc dust (500mg, 7.7mmol, 200eq) was added and the solution allowed to 
stir at room temperature. Samples were removed at hourly intervals and analysed by 
HPLC. After 2 hours all starting material had disappeared and the reaction was 
deemed complete. Co-injection with a sample of the peptide prepared with Cys(Trt) 
confirmed that cleavage of the protecting group had taken place. 
Yield 36mg; MS MALDI ToF 1210.36 (MH+, MW 1209.43); HPLC (Vydac Ci 8) Rt 
17.8mins, 56% MeCN; Amino Acid Analysis (24 hour hydrolysis) Aspi (1.12), 
(0.89), Ile2 (1.78), Leui (1.36), Tyrj (1.05), Phe! (1.09), Hisi (1.21).
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Synthesis of H2N-Ala-Cys(Pic)-Gly-OH (2.13)
The synthesis was carried out on a 0.25mmol scale starting from Fmoc-Gly 
functionalised Wang resin (400mg, 0.65mmol/g). Both residues were single coupled 
as the active HOCt ester. The resin was subjected to acidiolytic cleavage for 2 hours, 
the peptide precipitated into ice cold ether, centrifuged to a pellet and washed with 
ether (3 x 50ml). The peptide was dissolved in 50% v/v MeCN/H2O and 
lyophilysed.
*H NMR (250MHz, CD3OD 8H/ppm) 1.61 (3H, d, J = 7.1, CH3 ), 2.84 (1H, dd, J = 
7.8, 14.0, (3H Cys), 3.07 (1H, dd, J = 6.2, 14.0, p'H Cys), 3.93 - 4.13 (5H, m, picolyl 
CH2, aH Ala, CH2 Gly), 4.72 (1H, dd, J = 6.2, 7.8, aH Cys), 8.04 (2H, d, J = 6.6, 
aromatic CH), 8.80 (2H, d, J = 6.6, aromatic CH); HPLC (Vydac Cw) Rt 21.8mins, 
66% MeCN; MS MALDI-ToF 379.27 (K+ salt, C 14H2oN4O4S requires 340.4).
OXYTOCEV
Synthesis of Oxytocin with 2 Picolyl Protecting Groups (2.14)
The synthesis was carried out on a 0.25mmol scale, starting from Fmoc-Gly 
functionalised Wang resin (600mg, 0.44mmol/g). All amino acids were single 
coupled as their active HOCt ester. On completion of the synthesis the resin 
(820mg) was subjected to acidiolytic cleavage for 2 hours. The resin was removed 
by filtration and the peptide precipitated into ice cold ether, centrifuged to a pellet 
and washed a further 3 times with ether. The pellet was dissolved in MeCN:H2O 
(1:1) and lyophilised (Yield 190mg). 50 mg of this material was purified by semi 
preparative HPLC.
Yield 22mg; HPLC (Vydac C 18) Rt 16 mins, 53% MeCN; MS ES-MS 1192.71 (M+), 
MALDI-ToF 1193.88 (MH+) CssH-nNisO^ MW 1192.41; Amino Acid Analysis 
(24 hours hydrolysis) Asp! (1.03), Glui (1.08), Glyi (1.03), lid (0.97), Leui (1.04), 
Tyri (0.83), Proi (1.03); Ellmans Test-ve.
Cleavage of the picolyl groups (2.15)
Oxytocin(Pic) (2.14) (lOmg) was dissolved in a solution of 50% v/v AcOH/H2O (8 
ml) and activated zinc dust (500 mg) added to this and the solution left to stir at room 
temperature. After 30 mins an aliquot was removed and analysed by HPLC (Vydac
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Ci8), which indicated that cleavage of the picolyl groups was complete. The excess 
zinc dust was removed by filtration and the material desalted by semi preparative 
HPLC.
Yield 8.2mg; HPLC (Vydac Ci 8) Rt 18.4 mins, 59% MeCN; MS ES-MS 1010.8 
(M*), C43H67NiiOi3S2 MW 1010.19; Amino Acid Analysis (24 hours hydrolysis) 
Asp! (0.87), Glu! (1.07), Glyi (1.28), Cys2 (0.68), Ilei (1.03), Leui (1.39), Tyri 
(1.08), Proi (1.53); Ellmans Test + ve.
Disulfide Formation (2.16)
Oxytocin (2.15) (8mg) was added to a solution of 5% v/v DMSO/TFA (5ml) and left 
to stir at room temperature. Samples were removed hourly and analysed by HPLC 
(Vydac Ci 8). After 4 hours the reaction was deemed complete. The TFA and DMSO 
were removed in vacuo and the resulting yellow oil added drop-wise to ice cold 
ether. The precipitated peptide was centrifuged to a pellet and lyophilised from 
MeCN/H2O.
Yield 6.8mg; HPLC (Vydac dg K - 214nm) Rt 16.8 mins, 55% MeCN; MS ES-MS 
1008.6 (M4), C43H65NiiOi 3 S2 MW 1008.17; Amino Acid Analysis (24 hours 
hydrolysis) Aspj (0.97), Glui (1.04), Glyi (1.01), Cys2 (0.34), Ilei (0.96), Leui 
(1.03), Tyri (0.98), Proi (1.00); Ellmans Test- ve.
ENDOTHELEV-1
Synthesis of Endothelin-1 with 2 picolyl protected cysteine
The synthesis was carried out on a 0.25mmol scale starting from Fmoc-Trp(Boc) 
functionalised resin (500mg, 0.51mmol/g). All amino acids were single coupled as 
the active HOCt ester. On completion of the synthesis the resin was collected by 
filtration, washed with DMF, 1,4-dioxane, DCM, ether and dried. 
Yield 1.2g; Final Fmoc loading test 0.07mmol/g.
Loading Tbfmoc to the resin
Fmoc-ET-1-resin (700mg) was sonicated in 20% v/v piperidine/DMF for 20 minutes 
to remove the Fmoc protecting group. The resin was filtered, washed with DMF,
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1.4-dioxane, DCM, ether and dried. The resin was swollen in the minimum volume 
of dry DCM, Tbfmoc chloroformate (69mg, O.lSmmol, 3eq) and DIE A (8.5jil, 
O.OSmmol, leq) added and the mixture sonicated in the dark for 3 hours. The 
resulting Tbfrnoc-ET-1 -resin was collected by filtration washed with DCM, ether and 
dried.
Amino acid analysis (24 hours hydrolysis) Asp2 (2.09), Ser3 (2.24), Glui (1.42), 
Cys2 (1.24), Vali (1.58), Meti (0.92), Ile2 (2.34), Leu2 (3.40), Tyri (0.93), Phei 
(1.42), HiSl (1.21), Lys! (0.21).
Cleavage of Tbfmoc-ET-1 from the resin
Tbfmoc-ET-1-resin (700mg) was added to H2O (1ml), thioanisole (0.5ml), TIS 
(0.5ml), EDT (0.25ml), phenol (750mg) and allowed to stir under an atmosphere of 
nitrogen for 20 minutes. TFA (10ml) was then added and the mixture left to stir 
under nitrogen in the dark for 1 hour. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet, washed with ether (3 x 
50ml), dissolved in 50% v/v MeCN/H2O and lyophilised.
Yield 300mg; Amino acid analysis (24 hours hydrolysis) Asp2 (2.14), Ser3 (1.98), 
Glui (1.45), Cys2 (1.03), Vali (1.61), Met! (0.94), Ile2 (2.28), Leu2 (2.73), Tyri 
(1.05), Phei (1-45), Hisi (1.27), LySl (1.09).
Affinity Purification of Tbfmoc-ET-1-OH on Charcoal
Tbfmoc-ET-1-OH (60mg) was dissolved in 7M urea (25ml). Freshly washed 
charcoal (800mg) was added and the mixture vortexed for 10 minutes. The charcoal 
was centrifuged (3500rpm, lOmins) to a pellet. HPLC analysis of the supernatant 
confirmed all the Tbfmoc tagged material had bound to the charcoal. The charcoal 
pellet was washed with 50% v/v 7M urea/IPA (50ml, 5 times) until no absorbance at 
214nm was detectable by HPLC. The peptide was then cleaved from the charcoal by 
treatment with 10% v/v piperidine in 7M urea:EPA (1:1, 20ml), the charcoal was 
removed by centrifugation (3500rpm, lOmins), the pH of the supernatant adjusted to 
pH 4.5 with AcOH. The IP A was removed in vacuo and the material desalted on a 
Sephadex G50 (medium grade) gel filtration column using 20% v/v AcOH/H2O as 
eluent. Peptide containing fractions were pooled and lyophilised.
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Yield 14.7mg; MS ES-MS 2678.3 (MW 2677.89); HPLC (Vydac Ci8) Rt 20.8 mins, 
65% MeCN; Amino acid analysis (24 hours hydrolysis) Asp2 (2.08), Ser3 (2.31), 
Glui (1.33), Cys2 (1.31), Vali (1.26), Meti (0.89), Ile2 (1.77), Leu2 (2.14), Tyri 
(1.07), Phei (1.15), Hisi (1.09), LySl (1.11).
Disulfide formation in ET-1
ET-1 (4.5mg) was dissolved in 20% v/v AcOH/H2O (4ml) and left to stir for a few 
minutes. DMSO (1ml) was added to the solution to give a final concentration of 
20% DMSO. The solution was left to stir at room temperature and samples removed 
hourly for analysis by HPLC. After 3 hours the reaction appeared to be complete, 
the solvent was removed under reduced pressure and the resulting oil added dropwise 
to ether to precipitate the peptide. This was then isolated by centrifugation, washed 
with ether (3 x 20ml), dissolved in 50% v/v MeCN/H2O and lyophilised. 
Yield 3.2mg; HPLC (Vydac Ci8) Rt 19.6 mins, 62% MeCN.
Cleavage of the picolyl protecting groups
ET-1 (2mg) was added to 50% v/v AcOH/H2O and left to stir until all the peptide 
had dissolved. Freshly activated zinc dust (200mg) was added to this and the 
solution left to stir at room temperature. A sample was removed after 1 hour and 
analysed by HPLC, indicating that a mixture of products had been formed.
Reaction of L-Cystine with activated zinc dust
L-cystine (20mg) was dissolved in 50% v/v AcOH/H2O, activated zinc dust (200mg) 
added and the solution allowed to stir at room temperature. After 1 hour a sample 
was removed and analysed with Ellmans reagent. The solution turned bright yellow 
indicating cleavage of the disulfide bond had occurred.
Synthesis of Endothelin-1 with 4 Picolyl Protecting Groups (2.17)
The synthesis was carried out on a 0.25mmol scale, starting from Fmoc-Trp(Boc) 
functionalised Wang resin (600mg, 0.44mmol/g). All amino acids were single 
coupled as their active HOCt ester. The resin was collected by filtration, washed 
with DMF, 1,4-dioxane, DCM, ether and dried.
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Yield 1.4g; Final Fmoc loading test 0. Immol/g.
Loading Tbfmoc to the resin
Fmoc-ET-l(Pic)-resin (1.4g) was sonicated in 20% v/v piperidine/DMF for 20 
minutes to remove the Fmoc protecting group. The resin was filtered, washed with 
DMF, 1.4-dioxane, DCM, ether and dried. The resin was swollen in the minimum 
volume of dry DCM, Tbfmoc chloroformate (191mg, 0.42mmol, 3eq) and DIEA 
(24^1, 0.14mmol, leq) added and the mixture sonicated in the dark for 3 hours. The 
resulting Tbfmoc-ET-1-resin was collected by filtration washed with DCM, ether and 
dried.
Amino Acid Analysis (24 hours hydrolysis) Asp2 (2.03), Ser3 (1.79), Glu} (1.38), 
Vali (1.28), Meti (0.75), Ile2 (1.50), Leu2 (1.98), Tyri (1.30), Phei (1.45), Hisi (1.31), 
LySl (1.24).
Cleavage of Tbfmoc-ET-1 (Pic) from the resin
Tbfmoc-ET-1-resin (700mg) was added to H2O (1ml), thioanisole (0.5ml), TIS 
(0.5ml), EDT (0.25ml), phenol (750mg) and allowed to stir under an atmosphere of 
nitrogen for 20 minutes. TFA (10ml) was then added and the mixture left to stir 
under nitrogen in the dark for 1 hour. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet, washed with ether (3 x 
50ml), dissolved in 50% v/v MeCN/H2O and lyophilised.
Yield 404mg; Amino acid analysis (24 hours hydrolysis) Asp2 (2.01), Ser3 (2.08), 
Glui (1.21), Vali (1.28), Meti (0.92), Ile2 (1.71), Leu2 (2.38), Tyn (1.05), Phei 
(1.13), Hisi (1.12), Lys! (1.09).
Affinity Purification of Tbfmoc-ET-1 (Pic>OH on Polystyrene
Tbfmoc-ET-1 (Pic)-OH (195mg) was dissolved in 40% v/v AcOH/H2O (45ml). 
Polystyrene (3.7g) was added and the mixture vortexed for 10 minutes. The 
polystyrene was removed by filtration. HPLC analysis of the filtrate confirmed all 
the Tbfmoc tagged material had bound to the polystyrene. The polystyrene was 
washed with 40% v/v AcOH/H2O (50ml, 5 times) until no absorbance at 214nm was 
detectable by HPLC. The peptide was then cleaved from the polystyrene by
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treatment with 10% v/v piperidine in 60% v/v MeCN/H2O (50ml). The solution was 
acidified to pH 4.5 with AcOH, the MeCN removed in vacuo and the material 
desalted on a Sephadex G50 (medium grade) gel filtration column using 20% v/v 
AcOH/H2O as eluent. Peptide containing fractions were pooled and lyophilised. A 
final purification step by semi-preparative HPLC was required. 
Yield 14.7mg; HPLC (Vydac C 18 A, = 214nm) Rt 20 mins, 64% MeCN; MS ES-MS 
2859.9, MALDI-ToF 2861.87 (MW 2859.89); Amino Acid Analysis (24 hours 
hydrolysis) Asp2 (2.04), Ser3 (2.20), G!U! (1.25), Vali (1.25), Met! (0.78), Ile2 (1.88), 
Leu2 (2.20), Tyn (1.10), Phd (1.10), HiSl (1.10), Lysi (0.94); Ellmans Test-ve.
Cleavage of the picolyl groups (2.18)
Endothelin-l(Pic) (2.17) (lOmg) was dissolved in a solution of 50% v/v AcOH/H2O 
(8 ml) and activated zinc dust (500 mg) added to this and the solution left to stir at 
room temperature. HPLC analysis (Vydac Ci8) indicated that cleavage of the picolyl 
groups was complete after 1 hour. The excess zinc dust was removed by filtration 
and the material desalted by semi preparative HPLC.
HPLC (Vydac C 18) Rt 21.4 mins, 68% MeCN; MS ES-MS 2495.1, MALDI-ToF 
2497.31 (MW 2495.89); Amino Acid Analysis (24 hours hydrolysis) Asp2 (1.77), 
Ser3 (1.27), Gun (1.18), Cys4 (0.52), Vali (1.18), Met! (0.69), Ile2 (2.13), Leu2 
(2.10), Tyri (0.69), Phei (1.12), Hisi (1.02), Lysi (1.21); Ellmans Test + ve.
Bisulfide Formation (2.19)
Endothelin-1 (2.18) (5mg) was added to a solution of 5% v/v DMSO/TFA (5ml) and 
left to stir at room temperature. Samples were removed hourly and analysed by 
HPLC (Vydac Cig). After 6 hours the reaction was complete, giving two products of 
which the major was identified as the correct material form injection with a 
commercial standard (Peptide Institute INC., Japan). The TFA and DMSO were 
removed in vacuo and the resulting yellow oil was added drop-wise to ice cold ether. 
The precipitated peptide was centrifuged to a pellet dissolved in MeCN/H2O and 
purified by semi-preparative HPLC.
HPLC (Vydac Cig) Rt 19mins, 60% MeCN; MS ES-MS 2491.22 (MW 2491.89); 
Amino Acid Analysis (24 hours hydrolysis) Asp2 (2.02), Ser3 (1.96), Gluj (1.19),
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Cys4 (1.29), Vali (1.04), Meti (0.97), Ile2 (1.91), Leu2 (2.07), TyrT (0.64), Phei 
(0.97), Hisi (0.98), LySl (0.96); Ellmans Test-ve.
Chemical Synthesis and Purification of Deglycosylated Human Erythropoietin 
HPLC Conditions All HPLC analysis of dhEPO and dhEPO(Pic) was carried out 
using an Aquapore C4 column (dimensions 100 x 4.6mm, 7|um). Compounds were 
eluted from the column using a linear gradient of 10% - 90% MeCN in Milli-Q water 
over 30 minutes. All experiments were monitored at 214nm and also at 364nm for 
Tbfmoc material.
Synthesis of dhEPO
The synthesis was carried out on a O.lmmol scale using Fmoc-Arg(Pmc) 
functionalised Wang resin (580mg, 0.17mmol/g). Side chain protecting groups were 
as described in the text. All amino acids were single coupled as the active HOCt 
ester, with the exception of the last 20 residues which were double coupled. 
Approximately one third of the resin was removed after Ala777 and the synthesis 
continued to the end. The resin was washed with DMF, dioxane, DCM, ether and 
dried. 
Final Fmoc loading test 0.02mmol/g; Yield 1.5g.
Loading the Tbfmoc Group
Fmoc-dhEPO-resin (500mg) was sonicated in 20% v/v piperidine/DMF for 20 
minutes to remove the Fmoc protecting group. The resin was filtered, washed with 
DMF, 1.4-dioxane, DCM, ether and dried. The resin was swollen in the minimum 
volume of dry DCM, Tbfmoc chloroformate (13.75mg, 0.03mmol, 3eq) and DIEA 
(1.79|ul, O.Olmmol, leq) added and the mixture sonicated in the dark for 3 hours. 
The resulting Tbfmoc-dhEPO-resin was collected by filtration washed with DCM, 
ether and dried.
Amino Acid Analysis (24 hours hydrolysis) Asxi 2 (12.2), Thru (11.4), Ser10 (8.9), 
Glx, 9 (21.9), Gly9 (11.7), Ala19 (19.9), Cys4 (1.5), Vain (10.5), Met! (0.8), Ile5 (4.6), 
Leu23 (21.2), Tyr4 (4.2), Phe4 (4.3), His2 (2.8), Lys8 (8.7), Argl3 (13.5), Pro8 (9.4);
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(36 hours hydrolysis) Asxu (12.0), Thru (10.8), Serio (8.5), Glx19 (21.0), Gly9 
(11.7), Ala19 (19.1), Cys4 (1.2), Vain (10.0), Meti (0.9), Ile5 (4.6), Leu23 (18.7), Tyr4 
(4.8), Phe4 (4.5), His2 (2.8), Lys8 (8.6), Arg13 (13.1), Pro8 (10.4); (48 hours 
hydrolysis) Asx12 (11.9), Thrn (10.9), Ser]0 (8.4), Glx19 (20.9), Gly9 (11.6), Ala!9 
(19.5), Cys4 (1.1), Valn (10.4), Me^ (0.7), Ile5 (4.7), Leu23 (18.8), Tyr4 (4.9), Phe4 
(4.4), His2 (2.9), Lys8 (8.7), Arg13 (13.3), Pro8 (9.9).
Trial Cleavage of Tbfmoc-dhEPO-resin
Tbfmoc-dhEPO-resin (50mg) was added to H2O (1ml), thioanisole (0.5ml), TIS 
(0.5ml), EDT (0.25ml), phenol (750mg) and allowed to stir under an atmosphere of 
nitrogen for 20 minutes. TFA (10ml) was then added and the mixture left to stir 
under nitrogen in the dark. Samples were removed at hourly intervals and analysed 
by HPLC. After 4 hours no further change was noted in the HPLC trace and the 
cleavage was deemed complete.
Cleavage of Tbfmoc-dhEPO-resin
Tbfmoc-dhEPO-resin (500mg) was subjected to the acidiolytic cleavage conditions 
described above for 4 hours. The resin was separated by filtration and washed with a 
little TFA (~2ml). Addition of the filtrate to ice-cold ether resulted in the 
precipitation of the protein. This was centrifuged (3500rpm, 2mins) to a pellet and 
the supernatant discarded. The pellet was washed a further three times with ether, 
solubilised in 50% v/v MeCN/H2O and lyophilised.
Yield 247.9mg; Amino Acid Analysis (24 hours hydrolysis) Asxi2 (12.31), Thru 
(10.25), Ser10 (7.79), Glxi 9 (21.67), Gly9 (10.79), Alai 9 (18.68), Cys4 (1.98), Valn 
(13.30), Met] (1.19), Ile5 (5.05), Leu23 (25.50), Tyr4 (2.09), Phe4 (4.63), His2 (1.50), 
Lys8 (8.99), Arg13 (12.41), Pro8 (8.18).
Affinity Purification of Tbfmoc-dhEPO-OH on Charcoal
Tbfmoc-dhEPO-OH (140mg) was dissolved in 7M urea (25ml). Freshly washed 
charcoal (1.5g) was added and the mixture vortexed for 10 minutes. The charcoal 
was centrifuged (3500rpm, lOmins) to a pellet. HPLC analysis of the supernatant 
confirmed all the Tbfmoc tagged material had bound to the charcoal. The charcoal
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pellet was washed with 50% v/v 7M urea/IPA (50ml, 5 times) until no absorbance at 
214nm was detectable by HPLC. The protein was then cleaved from the charcoal by 
treatment with 10% v/v piperidine in 7M urea:IPA (1:1, 20ml), the charcoal was 
removed by centrifugation (3500rpm, lOmins), the pH of the supernatant adjusted to 
pH 4.5 with AcOH. The IPA was removed in vacuo and the material desalted on a 
Sephadex G50 (medium grade) gel filtration column using 30% v/v AcOH/H2O as 
eluent.
Amino Acid Analysis (24 hours hydrolysis) Asxi2 (12.07), Thr1} (10.38), Ser]0 
(8.24), Glxi9 (21.38), Gly9 (11.21), Alaw (18.30), Cys4 (2.09), Vain (11.30), Meti 
(0.25), Ile5 (4.60), Leu23 (23.68), Tyr4 (3.89), Phe4 (4.11), His2 (2.69), Lys8 (8.50), 
Argl3 (12.52), Pro8 (7.77).
Synthesis of dhEPO using the Picolyl Group for Cysteine Protection
The synthesis was carried out on a O.lmmol scale using Fmoc-Arg(Pbf) 
functionalised Wang resin (Ig, 0.097mmol/g). Side chain protecting groups were as 
described in the text, all four cysteine residues were protected with the picolyl group. 
All amino acids were single coupled as the active HOCt ester. Residues Tyr/5d- 
Lys752, Val 7^, Aig143, Lys140, Asp756-Ile732 and Pro727 , which were found to be low 
points from a previous synthesis, were coupled using the double cartridge method.
(JO
Approximately half of the resin was removed after Ala and the synthesis continued 
to Pro2. The resin was washed with DMF, dioxane, DCM, ether and dried. 
Final Fmoc loading test 0.02mmol/g; Yield 1.66g.
A'ra-(17-Tetrabenzo[fl,c,^,ilfluorenylmethoxycarbonyl)-/.-alanme(3.1)
L-Alanine (l.llg, 12.5mmol) was suspended in acetone (125 ml)/water (25ml). 
Tbfmoc-Cl (4.6g, 10 mmol) and AyV-dimethylaniline (3.6 ml, 28.75 mmol, 2.35 eq) 
were added and the mixture stirred in darkness at room temperature overnight. The 
solvent was removed under reduced pressure and the resulting orange residue 
dissolved in DCM (125 ml). This was washed with saturated citric acid (3 x 50 ml), 
H2O (6 x 50 ml), dried (MgSO4) and the solvent removed under reduced pressure. 
The resulting oil was dissolved in DCM and added drop wise to a large volume of 
hexane, with stirring, to yield an off white solid which was filtered, dried and
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purified by wet flash chromatography (CHCl3 :MeOH:AcOH; 97:2:1), to yield A^- 
(17-Tetrabenzo[a,c,gj]fluorenylmethoxycarbonyl)-L-alanine as an off white solid. 
Yield 897mg, 17.5%; Mp 133-135°C; Rf = 0.35 (CHCl3 :MeOH:AcOH; 97:2:1); MS 
(FAB) 512 (MH+); HRMS (FAB) 512.1861 (Nfflf requires 512.1862); *H NMR 
(250MHz, CDC13 8H/ppm) 1.33 (3H, d, J = 7.1, CH3 ), 4.22 - 4.35 (2H, m, aCH, 
NH), 4.73 (1H, dd, J = 5.2, 11.1, Tbfmoc CH), 5.03 - 5.19 (2H, m, CH2), 7.55 (8H, 
m, aromatic CH), 8.22 - 8.33 (2H, m, aromatic CH), 8.58 - 8.78 (6H, m, aromatic 
CH); 13C ^H) NMR (63MHz, CDC13 5C/ppm) 17.98 (q), 47.53 (d), 49.24 (d), 
69.15 (t), 123.09 (d), 123.19 (d), 123.48 (d), 124.32 (d), 125.01 (d), 125.09 (d), 
125.52 (d), 125.92 (d), 126.06 (d), 126.91 (d), 127.41 (d), 127.89 (d), 128.68 (s), 
130.19 (s), 130.30 (s), 131.49 (s), 136.59 (s), 136.92 (s), 141.15 (s), 142.57 (s), 
155.72 (s), 176.99 (s); FTIR vmax/cm'1 (bromoform) 1141 (C-O), 1507 (aromatic), 
1711 (C=O & urethane), 3017 (aromatic CH), 3419 (OH); A,max/nm (MeOH, 
e/dn^morW1) 378 (17374), 363 (18396), 299 (43946), 287 (36281), 276 (32193), 
258 (66430), 251 975628), 237 (56721); [ajo24 -19.9° (c = 1, DMF); HPLC 
(Aquapore C4, 10% - 40% B, 5 mins, 40% - 90% B, 41 mins, A = 364nm) 59% 
MeCN,Rt 18.4mins.
Coupling of Tbfmoc-Ala-OH
DhEPO(Pic) resin (1.66g, 0.33mmol) was sonicated in 20% v/v piperidine/DMF for 
20 minutes to remove the N0 protecting group. The resin was washed with DMF, 
dioxane, DCM, ether and dried.
The resin was swollen in the minimum volume of DCM and Tbfmoc-Ala-OH (3.1) 
(68.7mg, 0.13mmol, 4eq), HOBt (18mg, 0.13mmol, 4eq) and DIC (21^1, O.Bmmol, 
4eq) added. The resin was then sonicated in the dark at room temperature for 90 
minutes. The resin was collected by filtration, washed with DCM, ether and dried. 
Amino Acid Analysis (24 hours hydrolysis) Asxi2 (13.26), Thrn (9.97), Ser10 (6.31), 
Glxi9 (21.44), Gly9 (10.74), Alai9 (20.96), Vain (10.10), Met! (0.63), Ile5 (6.61), 




Cleavage of Tbfmoc-dhEPO(Pic) Resin
Resin bound Tbfmoc-dhEPO(Pic) (500mg) was stirred in TFA (10ml) containing 
H2O (1ml), thioanisole (0.5ml), triisopropylsilane (0.5ml), EDT (0.25ml) and phenol 
(750mg) in the absence of light. After 4 hours the resin was removed by filtration 
and the filtrate added to ice cold ether. The resulting precipitate was centrifuged to a 
pellet, washed with ether (3 x 50ml) and the crude protein dissolved in MeCN/H2O 
and lyophilised.
Yield 268mg; Amino Acid Analysis (24 hours hydrolysis) Asx]2 (12.82), Thru 
(9.31), Ser10 (7.17), Glxi 9 (20.27), Gly9 (9.85), Ala!9 (19.54), Vain (11.10), Met! 
(1.74), Ile5 (6.98), Leu23 (22.61), Tyr4 (3.62), Phe4 (4.15), His2 (2.11), Lys8 (8.06), 
Argi 3 (l 1.29), Pro8 (8.34).
Tbfmoc/Polystyrene Affinity Purification of dhEPO(Pic)
Tbfmoc-dhEPO(Pic) (96mg) was dissolved in 40% v/v AcOH/H2O (40ml). 
Polystyrene (1.8g) was added to this and the solution vortexed for 10 minutes and the 
polystyrene centrifuged to a pellet. HPLC analysis of the supernatant confirmed that 
all the Tbfmoc tagged material had bound to the polystyrene. The polystyrene pellet 
was washed with 40% v/v AcOH/H2O (3 x 50ml) and H2O (2 x 50ml). The protein 
was then cleaved from the Tbfmoc-polystyrene by treatment with a solution of 10% 
v/v piperidine in 60% v/v MeCN/H2O. The MeCN was removed in vacuo and the 
material desalted on a Sephadex G50 (medium grade) gel filtration column using 
20% v/v AcOH/H2O as eluent.
Yield 5mg; Amino Acid Analysis (24 hours hydrolysis) Asx]2 (12.37), Thru (7.89), 
Ser10 (4.73), Glx19 (20.48), Gly9 (9.34), Ala19 (20.79), Vain (11.92), Meti (1.19), Ile5 
(6.42), Leu23 (23.66), Tyr4 (3.75), Phe4 (4.56), His2 (2.06), Lys8 (8.82), Arg13 
(12.64), Pro8 (8.39).
Removal of Tbfmoc and Cleavage of dhEPO(Pic) from the Resin
Resin bound Tbfmoc-dhEPO(Pic) (200mg) was sonicated in a solution of 20% v/v 
piperidine/DMF (10ml) for 20 minutes. The resin was then collected by filtration, 
washed with DMF, dioxane, DCM, ether and dried. Cleavage of the protein from the 
resin and side chain protecting groups was accomplished by stirring the resin in TFA
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(10ml) containing H2O (1ml), thioanisole (0.5ml), triisopropylsilane (0.5ml), EOT 
(0.25ml) and phenol (750mg) in the absence of light for 4 hours. The resin was 
removed by filtration and the filtrate added to ice cold ether. The resulting 
precipitate was centrifuged to a pellet, washed with ether (3 x 50ml), dissolved in 
50% v/v MeCN/H2O and lyophilised to yield dhEPO(Pic) as a white fluffy solid. 
Yield 90.5mg; Ammo Acid Analysis (24 hours hydrolysis) Asx!2 (12.51), Thru 
(9.36), Ser10 (7.34), Glx19 (21.60), Gly9 (9.14), Ala!9 (19.85), Vain (11.42), Meti 
(1.58), Ile5 (6.63), Leu23 (22.13), Tyr4 (3.74), Phe4 (3.92), His2 (2.05), Lys8 (8.06), 
Arg13 (11.46),Pro8 (8.19).
Sephadex G75 Gel Filtration of dhEPO(Pic)
Column Conditions Gel filtration was carried out on a Sephadex G75 (superfine
grade) column (diameter = 1.5cm, length = 90cm) pre-equilibrated with 20% v/v
AcOH/H2O. A solution of dhEPO(Pic) (lOmg) in 6M urea, 0.2M NaCl, 0.1M
phosphate buffer pH 7.5 (400(il) was applied to the column. The protein was eluted
from the column using 20% v/v AcOH/H2O (lOml/h) and fractions collected at
hourly intervals. All fractions were analysed by UV (280nm) and a sample of all
protein containing fractions (1ml) removed and lyophilised. Analysis of this material
by SDS-PAGE identified the fractions containing dhEPO, these were pooled and
lyophilised. The above procedure was repeated to generate larger quantities of
material. Generally three applications of material to the column was required for
purification.
1 st Pass Down Column Amino Acid Analysis (24 hours hydrolysis) Asx]2 (12.08),
Thru (9.15), Ser]0 (7.30), Glx]9 (19.20), Gly9 (9.88), Ala]9 (20.93), Valn (13.21),
Meti (1.42), fles (5.88), Leu23 (22.31), Tyr4 (3.02), Phe4 (4.44), His2 (3.20), Lys8
(8.24), Argl3 (10.71), Pro8 (8.12).
2nd Pass Down Column Amino Acid Analysis (24 hours hydrolysis) Asxi2 (11.83),
Thru (8.94), Ser10 (7.87), GIxi 9 (19.56), Gly9 (9.18), Ala19 (18.86), Vain (12.20),
Metj (2.75), Ile5 (7.79), Leu23 (21.98), Tyr4 (2.14), Phe4 (4.66), His2 (3.87), Lys8
(7.96), Arg, 3 (11.41), Prog (7.23).
3rd Pass Down Column Amino Acid Analysis (24 hours hydrolysis) Asx^ (11.84),
Thm (9.71), Ser10 (8.57), Glx19 (19.76), Gly9 (9.18), Ala19 (18.94), Val n (11.42),
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Met! (1.19), Ile5 (5.23), Leu23 (22.91), Tyr4 (3.63), Phe4 (4.01), His2 (2.16), Lys8 
(7.91), Arg13 (1 1.88), Pro8 (8.19); TV-Terminal Sequencing cycle 1 - Ala 47.4/nnol; 
cycle 2 Pro 44.4/7mol; cycle 3 Pro 27.7/?mol; cycle 4 not determined; cycle 5 Leu 
14.2/wnol.
Tryptic Digest of dhEPO(Pic)
DhEPO(Pic) (0.5mg) was dissolved in 6M urea, 0.2M phosphate buffer, pH 8 
(200^1) and trypsin (5% w/w) added. The solution was mixed and incubated at 37°C. 
After 2 hours lOOjul of the solution was removed and the digest stopped with the 
addition of 6N HC1 (5(11). The solution was separated using analytical HPLC (Vydac 
Cig, 2ml loop, Iml/min, 10-90% MeCN, 60mins) and the samples analysed by 
MALDI-ToF MS. After 5 hours the remaining solution was treated in the same 
manner. The HPLC trace was identical indicating that the digest was complete after 
2 hours.
m/z (MALDI-ToF) 797.49 (MH+ Leu5-Arg70, requires 797.36) 738.96 (MH+ Tyr75- 
20 7 ^5 +Lys, requires 736.42) 2868.6 (MH Gh-Lys, requires 2871.2) 969.61 (MK 
Val^-Lys52, requires 927.47) 2548.76 (MNa+ Met5¥-Arg76, requires 2526.34) 
2359.52 (MH+ Gly77-Lysp7, requires 2359.2) 602.57 (MH+ Ala^-Arg703, requires 
602.36) 803.16 (MH+ Ser7^-Arg770, requires 803.49) 588.99 (Mrf" Ala777-Lys77*, 
requires 587.35) 1465.21 (MH^ Glu777-Arg737, requires 1465.76) 923.07 (MH+ 
Thr73j?-Arg759 , requires 924.48) 922.99 (MNa+ Val7^-Arg750 , requires 898.45) 
1005. 16 MH+ Leu755-Arg752, requires 1003.42).
Isoelectric Focusing of dhEPO(Pic)
Ampholytes (pH 3 - 10, Fluka, 1ml) were added to a solution of dhEPO(Pic) (2mg) 
in 6M urea (17ml) and the solution added to the focusing chamber of the Rotofor® 
cell. The system was allowed to reach thermal equilibrium at the cooling 
temperature of 5°C for 10 minutes. Constant power of 15W was applied to the 
system and the increase in voltage noted over time. After 2 hours the voltage 
stabilised and the run was left for a further 30 minutes before harvesting. The pH of 
the resulting fractions was checked and each was analysed for protein content by 
HPLC. All protein was found in fractions 19 and 20, indicating a pi of 10.0.
97

















































Molecular Weight Determination of dhEPO(Pic) by FPLC
Column conditions Analysis was carried out using a Superdex  75 HR 10/30
column (column volume Vt 44.93cm3 ) pre-equilibrated with 6M urea, 0.2M NaCl,
0. 1M phosphate buffer pH 7.5 at a flow rate of 0.5ml/min.
The column void volume was calculated using blue dextran (MWt 2,000,000, V0
8.51ml). Calibration of the column was achieved using a series of molecular weight
standards and the elution volume (Ve) of each measured with monitoring at 280nm,
ovalbumin (MWt 43,000, Ve 8.63ml), chymotrypsinogen A (MWt 25,000, Ve
8.77ml), ribonuclease A (MWt 13,700, Ve 9.09ml). The elution volume for
dhEPO(Pic) was 8.94ml.
Cleavage of the Picolyl Groups from dhEPO(Pic)
A sample of dhEPO(Pic) (3 nig) was dissolved in 50% v/v AcOH/H2O and activated 
zinc dust (300mg) added. The resulting solution was left to stir for 2 hours at room 
temperature. The excess zinc dust was then removed by filtration and the material 
separated by analytical HPLC.
Yield l.Smg; Ellmans Test +ve; Amino Acid Analysis (24 hours hydrolysis) Asx]2 
(12.31), Thru (9.47), Ser10 (8.40), Glx19 (21.33), Gly9 (9.64), Alai 9 (21.71), Cys4 
(0.77), Vain (12.05), Meti (1.71), Ile5 (5.80), Leu23 (23.84), Tyr4 (3.00), Phe4 (4.18), 
His2 (2.26), Lys8 (7.89), Argn (1 1.67), Pro8 (8.43).
Transfer Active Ester Condensation of dhEPO 
9-FluorenylmethoxycarbonyI Hydrazine (4.9)
A solution of 9-fluorenylmethylchloroformate (Ig, 3.8mmol) in MeCN (130 ml), was 
added dropwise to hydrazine monohydrate (6 ml, 0.12mol) with stirring over a 
period of 30 mins. The resulting turbid solution was then allowed to stir for a further
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30 mins at room temperature in the absence of light. The solvent was removed under 
reduced pressure to yield 9-fluorenylmethoxycarbonyl hydrazine as a white solid 
which was washed with copious quantities of ethanol and dried in vacua. 
Yield (930mg, 95%); Mp 172-174°C (lit 172-174°C)8 ; MS (FAB) m/z 255 (MH+); 
HRMS 255.1134 (MH+ requires 255.1134); CHN found, C 70.76%, H 5.38%, N 
11.08% (C 15H14N2O2 requires C 70.85%, H 5.55%, N 11.02%); *H NMR (250MHz, 
d6DMSO 8H/ppm) 4.08 (2H, br, NH2), 4.25 (3H, m, fluorenyl CH and CH2 ), 7.35 
(4H, m, aromatic CH), 7.67 (2H, d, J = 7.6, aromatic CH), 7.87 (2H, d, J = 7.6, 
aromatic CH), 8.35 (1H, br, NH); 13C ^H) NMR (63MHz, d6DMSO 5C/ppm) 
46.77 (d), 65.73 (t), 120.12 (d), 120.20 (d), 121.47 (d), 125.33 (d), 127.17 (d), 127.38 
(d), 127.73 (d), 129.01 (d), 137.52 (s), 139.51 (s), 140.79 (s), 143.91 (s), 158.27 (s); 
FTIR vmax/cm'1 (bromoform) 1141 (C-O), 1512 (aromatic), 1694 (C=O), 2899, 
2956 (CH), 3018 (aromatic CH), 3207, 3315 (NH); A,max/nm (MeOH, e/dm3mol' 
W1) 300 (5186), 289 (5186), 265 (16510).
3-Hydroxymethyl-3-nitro-l,5-dioxaspiro-5:5-undecane (4.11)
Cyclohexanone (35ml; 0.34mol) and /ra(hydroxymethyl)nitromethane (51g; 
0.34mol) were refluxed in sodium dried benzene (250ml) with a catalytic amount of 
/7-TSA using a Dean and Stark trap for 2.5 hours. The reaction was allowed to cool 
to room temperature, the organic layer washed with H2O (2 x 100ml), dried (MgSO4) 
and the solvent removed under reduced pressure to yield 3-hydroxymethyl-3-nitro- 
l,5-dioxaspiro-5:5 undecane as an off white solid which was recrystallised from 
EtOAc / hexane.
Yield 42g, 54%; Mp 95-97°C (lit 97-98°C)9 ; MS FAB m/z = 232 (MH1"); HRMS 
232.1189 (MH+ requires 232.1185); CHN found C 52.03%, H 7.41%, N 5.97% 
(Ci0H17N05 requires C 51.94%, H 7.41%, N 6.06%); *H NMR (250MHz, CDC13 
8H/ppm) 1.37-1.75 (10H, m, aliphatic ring CH2), 2.57 (1H, br, OH), 4.02 (2H, s, 
CHaOH), 4.03 (2H, d, J = 12.66, axial dioxan ring 2 x CH), 4.38 (2H, d, J = 12.66, 
equatorial dioxan ring 2 x CH); 13C {'H} NMR (63MHz, CDC13 5C/ppm) 22.25 (t), 
22.37 (t), 25.19 (t), 31.66 (t), 32.19 (t), 60.51 (t), 63.38 (t), 86.65 (s), 99.52 (s); FTIR 
Vmax/cm"1 (bromoform) 1112 (C-O), 1346, 1443 (NO2), 1544 (C-NO2), 2856, 2936 
(CH), 3417 (OH); Xmax/nm (MeOH, eMui'moI^cm'1) 271 (770).
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Pentafluorophenol carbonate of 3-hydroxymethyl-3-nitro-l,5-dioxaspiro-5:5 
undecane (4.12)
3-Hydroxymethyl-3-nitro-l,5-dioxaspiro-5:5 undecane (4.11) (11.55g; 50mol), 
triphosgene (5g; 16.6mol) and DffiA (8.7ml; 50mol) were stirred in sodium dried 
toluene under an inert atmosphere of dry N2 . After 15 mins a white precipitate 
formed (DIEA.HC1) and the first stage of the reaction was deemed complete. The 
chloroformate was then reacted immediately in situ by the addition of a mixture of 
pentafluorophenol (10. Ig; 55mol) and DffiA (8.7ml; 50mol) dissolved in the 
minimum volume of toluene. The reaction was stirred for a further 15 mins then 
rapidly washed with iced water (2 x 100ml), brine (100ml), dried (MgSO4) and the 
solvent removed under reduced pressure to yield the pentafluorophenol carbonate of 
3-hydroxymethyl-3-nitro-l,5-dioxaspiro-5:5 undecane as a white solid which was 
recrystallised from EtOAc / hexane.
Yield 12.35g; 56%; Mp 119-122°C (lit 121-123°C) 10 ; MS (FAB) m/z - 442 (MH+); 
HRMS (FAB) 442.0925 (MH+ requires 442.0925); CHN found C 46.39%, H 3.76%, 
N 3.19% (Ci 7Hi6F5NO7 requires C 46.27%, H 3.65%, N 3.17%); XH NMR 
(250MHz, CDC13 8H/ppm) 1.24 - 1.84 (10H, m, aliphatic ring CH2), 4.09 (2H, J = 
12.66, axial dioxane ring 2 x CH), 4.43 (2H, d, J = 12.66, equatorial dioxane ring 2 x 
CH), 4.49 (2H, s, CH2O); 13C {1H} NMR (63MHz, CDCI3 5C/ppm) 22.23 (t), 22.35 
(t), 25.14 (t), 29.79 (t), 33.86 (t), 60.41 (t), 68.26 (t), 83.22 (s), 99.99 (s), 126.17 - 
128.34 (aromatic CF), 129.32 (s), 150.45 (s); 19F {'H} NMR (250MHz, CDC13 
5F/ppm) 10.95, 11.26, 11.78 (CF); FTIR v^/cm'1 (bromoform) 1140 (C-O), 
1392, 1448 (NO2), 1521 (aromatic), 1547 (C-NO2), 1786 (C-O), 2873, 2940, 2957 
(CH), 3379 (OH); A^/nm (MeOH, e/dm'mol'W1) 263 (1208), 243 (735).
7Va-9-Fluorenylmethoxycarbonyl-N£-l,5-dioxaspiro-5:5-undecane-3-nitro-3-
methoxycarbonyl-lysine (4.13)
Fmoc-Lys-OH (5g; 13.5mmol) was suspended in l,4-dioxane:H2O (2:1, 150ml) and 
triethylamine (3.75ml; 27mmol) added. The solution was cooled to 0°C and the 
pentafluorophenol carbonate of 3-hydroxymethyl-3-nitro-l,5-dioxaspiro-5:5 
undecane (4.12) (6.17g; 14mmol) added. The temperature was allowed to rise and 
the reaction stirred at room temperature overnight. The solution was filtered to
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remove any insoluble material and the solvent removed in vacuo. The resulting 
residue was dissolved in EtOAc (100ml) and washed with brine (3 x 50ml), dried 
(MgSO4) and the solvent removed under reduced pressure. The resulting yellow 
foam was dissolved in DCM and purified by wet flash chromatography 
(DCM:MeOH; 9:1) to yiQldNa-9-fluorenylmethoxycarbonyl-N£-l,5-dioxaspiro-5:5- 
undecane-3-nitro-3-methoxycarbonyl-lysine as a white solid. 
Yield 7.23g, 85%; Tic Rf 0.31 (DCM:MeOH; 9:1); Mp 176-177°C (lit 172°C)10; MS 
(FAB) m/z = 626 (MH4); HRMS (FAB) 626.2694 (MH+ requires 626.2714); *H 
NMR (200MHz, 8H/ppm) 1.16 - 1.98 (18H, m, aliphatic ring CH2, lysine side chain 
CH2),4.1 - 4.4 (10H, m, dioxane ring CH2, aH, Fmoc CH, Fmoc CH2, CH2O), 7.2 - 
7.4 (4H, m, aromatic CH), 7.7 (2H, d, J = 7.3, aromatic CH), 7.9 (2H, d, J = 7.3, 
aromatic CH); 13C {1B} NMR (63MHz, 8C/ppm) 22.2 (t), 22.6 (t), 22.8 (t), 25.0 (t), 
28.3 (t), 29.3 (t), 31.1 (t), 31.9 (t), 46.9 (d), 55.2 (d), 60.5 (t), 63.2 (t), 65.4 (t), 85.6 
(s), 98.7 (s), 120.2 (d), 125.4 (d), 127.2 (d), 127.7 (d), 140.6 (s), 144.1 (s), 155.0 (s), 
155.8 (s), 176.1 (s); FTIR v^/cnf1 (bromoform) 1140 (C-O), 1341, 1446 (NO2), 
1515 (aromatic), 1549 (C-NO2), 1709 (C=O), 2859, 2937 (CH), 3020 (aromatic CH), 
3331 (NH), 3416 (OH); Xmax/nm (MeOH, e/dnfaorW1) 300 (7422), 288 
(10156), 265 (23438); [a]i>24 -5.8° (c 1.0, DMF); HPLC (Aquapore RP18 C18, A, = 
214nm) 66% MeCN, Rt 21.2min.
Synthesis of Fragment 1 (4.19)
The synthesis was carried out on a O.lmmol scale, starting from Fmoc-Arg(Pbf) 
functionalised Wang resin (Ig, O.lmmol/g). All amino acids were single coupled as 
their active HOCt ester. On completion of the synthesis the resin (600mg) was 
subjected to acidiolytic cleavage for 4 hours. The resin was removed by filtration 
and the peptide precipitated into ice cold ether, centrifuged to a pellet and washed a 
further 3 times with ether. The pellet was then lyophilised from MeCN:H2O (Yield 
152mg). Purification of this material was achieved by semi-preparative HPLC. 
Yield 14.2mg; HPLC (Vydac C8) Rt 21.2 mins, 67% MeCN; MS ES-MS 5158.8, 
(MW 5157.26); Amino Acid Analysis (24 hours hydrolysis) Asp3 (3.01), Thr5 
(3.73), Sen (1.07), Glui (0.99), Gly3 (2.62), Ala3 (2.60), Vali (1.87), Ilei (1.06), Leu5 
(5.46), Tyr2 (1.51), Phe3 (3.83), Lys3 (3.68), Arg6 (5.56), PrOl (1.01).
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Synthesis of Fragment 2 (4.18)
The synthesis was carried out on a O.lmmol scale, starting from semi-carbazide 
linker resin (600mg, 0.19mmol/g). All amino acids were single coupled as their 
active HOCt ester. On completion of the synthesis the resin (450mg) was subjected 
to acidiolytic cleavage for 4 hours. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet and washed a further 3 
times with ether. The pellet was then lyophilised from MeCN:H2O (Yield 120mg). 
This material was purified by semi-preparative HPLC
Yield 22mg; HPLC (Vydac Ci 8) Rt 14.8 mins, 50% MeCN; MS ES-MS 2883.9, 
MALDI-ToF 2889.68 (MW 2885.21); Amino Acid Analysis (24 hours hydrolysis) 
Aspi (1.07), Thr2 (1.67), Ser3 (2.00), Glu2 (2.12), Glyi (1.18), Ala* (5.90), Ilej (1.07), 
Leu5 (4.93), Lysi (1.68), Arg2 (2.36), Pro2 (2.17).
Synthesis of Fragment 3 (4.17)
The synthesis was carried out on a O.lmmol scale, starting from semi-carbazide 
linker resin (600mg, 0.23mmol/g). All amino acids were single coupled as their 
active HOCt ester. On completion of the synthesis the resin (500mg) was subjected 
to acidiolytic cleavage for 4 hours. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet and washed a further 3 
times with ether. The pellet was then lyophilised from MeCN:H2O (Yield 140mg). 
This material was purified by semi-preparative HPLC.
Yield 55mg; HPLC (Vydac C 18) Rt.17.4 mins, 56% MeCN; MS ES-MS 3959.69 (- 
NH), MALDI-ToF 3973.72, (MW 3974.29), Amino Acid Analysis (24 hours 
hydrolysis) Asp2 (2.24), Ser4 (2.74), Glu5 (5.31), Gly2 (2.25), Ala4 (4.14), Val4 
(4.84), Leu8 (6.45), Efisi (1.23), LySl (1.22), Argi (1.07), Pro2 (2.10).
Synthesis of Fragment 4 (4.16)
The synthesis was carried out on a O.lmmol scale, starting from semi-carbazide 
linker resin (600mg, 0.23mmol/g). All amino acids were single coupled as their 
active HOCt ester. On completion of the synthesis the resin (700mg) was subjected 
to acidiolytic cleavage for 4 hours. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet and washed a further 3
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times with ether. The pellet was then lyophilised from MeCN:H2O (Yield 230mg). 
This material was purified by semi-preparative HPLC.
Yield 78mg; HPLC (Vydac C8) Rt 20 mins, 64% MeCN; MS ES-MS 4883.1, (MW 
4882.2); Ammo Acid Analysis (24 hours hydrolysis) Asp4 (3.79), Thr2 (1.79), Sen 
(0.87), Glu7 (7.38), Gly2 (2.12), Ala3 (2.81), Val5 (5.09), Meti (1.12), Ilei (0.94), 
Leu! (0.96), Tyn (0.99), Phei (1.11), HiSl (0.98), Lys2 (2.10), Argl (1.07), PrOl 
(1.38).
Synthesis of Fragment 5 (4.15)
The synthesis was carried out on a O.lmmol scale, starting from semi-carbazide 
linker resin (Ig, O.llmmol/g). All amino acids were single coupled as their active 
HOCt ester. The synthesis was stopped after coupling of Pro2 to enable manual 
coupling of Tbfmoc-Ala-OH. The resin (1.2g, 0.084mmol/g) was swollen in dry 
DCM and Tbfmoc-Ala-OH (174mg, 0.34mmol, 4eq), HOCt (53.4mg, 0.34mmol, 
4eq), DIG (53jal, 0.34mmol, 4eq) added. The mixture was sonicated in the dark for 3 
hours after which time the resin was separated by filtration, washed with DCM, ether 
and dried. On completion of the synthesis the resin (600mg) was subjected to 
acidiolytic cleavage for 4 hours. The resin was removed by filtration and the peptide 
precipitated into ice cold ether, centrifuged to a pellet and washed a further 3 times 
with ether. The pellet was then lyophilised from MeCN:H2O (Yield 170mg). This 
material was purified by semi-preparative HPLC.
Yield 63mg; HPLC (Vydac C8) Rt 25.2 mins, 77% MeCN; MS ES-MS 3905.6, 
(MW 3904.6); Amino Acid Analysis (24 hours hydrolysis) Asp2 (2.10), Thr2 (1.79), 
Sen (0.76), Glu4 (4.29), Glyi (1.02), Ala3 (2.95), Vali (1.22), Ile2 (1.89), Leu4 (4.07), 
Tyn (0.84), LySl (1.11), Arg3 (3.06), Pro2 (2.00).
Attempted Ligation of Fragment 5 and Fragment 4
Fragment 5 (4.15) (lOmg, 2.56jLimol) and HOCt (157mg, Immol) were added to dry 
DMF (1ml) and left to stir under an atmosphere of dry Argon. 'BuONO (3.04^1, 
25.6|iimol, lOeq) was added and the solution left to stir at room temperature 
overnight. Analysis by HPLC indicated the formation of 2 new products. Fragment 
4 (4.16) (13.7mg, 2.82|umol, l.leq) and DDEA (250^1, 1.45mmol) were dissolved in
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dry DMF (400^1) and added to the reaction. After one hour a sample of the reaction 
was analysed by HPLC, indicating the disappearance of all 364nm active material.
Tbfmoc Cleavage Studies
General Procedure Tbfmoc-Leu-OH (2mg, 3.6nmol) and HOCt (157mg, Immol) 
were dissolved in dry DMF (1ml) under an atmosphere of dry Argon. Base 
(1.45mmol) was added to this and the solution left to stir at room temperature. 
Samples were removed hourly and analysed by HPLC at 364nm to check for the 














Synthesis of fragment 5 using the Fmoc group for N° protection (4.20)
The synthesis was carried out on a 0. Immol scale, starting from chlorotrityl 
hydrazide linker resin (TOOmg, 0.13mmol/g). All amino acids were single coupled as 
their active HOCt ester. On completion of the synthesis the resin (900mg) was 
subjected to acidiolytic cleavage for 4 hours. The resin was removed by filtration 
and the peptide precipitated into ice cold ether, centrifuged to a pellet and washed a 
further 3 times with ether. The pellet was then lyophilised from MeCN:H2O (Yield 
180mg). This material was purified by semi-preparative HPLC. 
Yield 82mg; HPLC (Vydac C 18) Rt 24.2 mins, 74% MeCN; MS ES-MS 3362.9, 
(MW 3362); Amino Acid Analysis (24 hours hydrolysis) Asp2 (2.01), Thr2 (1.76), 
Sen (0.88), Glii4 (4.29), Glyj (1.14), Ala3 (2.93), Vali (1.26), Ile2 (1.92), Lem (3.98), 
Tyn (0.78), LySl (1.19), Arg3 (3.01), Pro2 (1.83).
Attempted Ligation of Fragment 5 and Fragment 4
Fragment 5 (4.20) (5mg, 1.37|umol) and HOCt (157mg, Immol) were added to dry 
DMF (1ml) and left to stir under an atmosphere of dry Argon. {BuONO (1.63(il, 
13.7|Limol, lOeq) was added and the solution left to stir at room temperature. HPLC
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analysis indicated some reaction had occurred after 6 hours. Fragment 4 (4.16) 
(6.7mg, 13.7jLimol, l.eq) and DIEA (250ul, 1.45mmol) were dissolved in dry DMF 
(400^1) and added and the reaction left to stir at room temperature overnight. The 
material was desalted on a Sephadex G50 (medium grade) gel filtration column using 
20% v/v AcOH/H2O as eluent. Peptide containing fragments were pooled and 
lyophilised.
MS ES-MS 4865.14 (fragment 4 MW 4883), 3663.34 (fragment 5 MW 3662).
Fmoc-Glu-Val-Trp-Gln-Gly-CONHNHCONH2 (4.21)
The synthesis was carried out on a 0.25mmol scale, starting from semi-carbazide 
linker resin (750mg, 0.36mmol/g). All amino acids were single coupled as their 
active HOCt ester. On completion of the synthesis the resin (850mg) was subjected 
to acidiolytic cleavage for 2 hours. The resin was removed by filtration and the 
peptide precipitated into ice cold ether, centrifuged to a pellet and washed a further 3 
times with ether. The pellet was then lyophilised from MeCN:H2O to yield the 
peptide as a white fluffy solid which was used without further purification. 
Yield 62mg; HPLC (Vydac C ]8) Rt 20.8 mins, 65% MeCN; MS MALDI-ToF 
896.46, (MW 896.64); Amino Acid Analysis (24 hours hydrolysis) Glx2 (1.96), Glyi 
(0.99), Vali (1.05).
H2N-Leu-Ala-Leu-Leu-Ser-OH (4.22)
The synthesis was carried out on a 0.25mmol scale, starting from Fmoc-Ser(*Bu) 
functionalised Wang resin (700mg, 0.34mmol/g). All amino acids were single 
coupled as their active HOCt ester. On completion of the synthesis the resin 
(850mg) was subjected to acidiolytic cleavage for 2 hours. The resin was removed 
by filtration and the peptide precipitated into ice cold ether, centrifuged to a pellet 
and washed a further 3 times with ether. The pellet was then lyophilised from 
MeCN:H2O to yield the peptide as a white fluffy solid which was used without 
further purification.
Yield 140mg; HPLC (Vydac C 18) Rt 15 mins, 50% MeCN; MS MALDI-ToF 





Semi-carbazide peptide (4.21) (lOmg, O.Ollmmol) and HOCt (235.5mg, l.Smmol) 
were added to dry DMF (Aldrich) (1ml) and left to stir under an atmosphere of dry 
argon. 'BuONO (2.6^1, 0.022mmol, 2eq) was added and the reaction left to stir at 
room temperature. After 2 hours an aliquot was removed and analysed by HPLC 
(Vydac Ci 8). After 4 hours there was no further reaction and 80% of the semi- 
carbazide was deemed to have converted to the active ester. Free amino peptide 
(4.22) (5.66mg, O.Ollmmol, leq) and DffiA (384|ul, 2mmol) were added and the 
reaction left to stir at room temperature. A sample was removed after 1 hour and 
analysed by HPLC, indicating all starting material had disappeared. The DMF was 
removed in vacua and the resulting oil added to diethyl ether to precipitate the 
peptide. The peptide was centrifuged to a pellet and lyophilised from 50% v/v 
MeCN/H2O.
Yield 2.1mg; HPLC (Vydac Ci 8) Rt 25.4mins, 78% MeCN; MS ES-MS 1337.79, 
(MW 1337.28); Amino Acid Analysis (24 hours hydrolysis) Sen (0.62), Glx2 (2.02), 
Glyi (1.01), Al^ (0.92), Vali (1.16), Leu3 (3.23).
Synthesis of l-Hydroxy-4-ethoxy-carbonyl-l,2,3-triazole (HOCt) 
Ethyl diazoaceatate
A solution of glycine ethyl ester hydrochloride (210g, 15mol) in water (300ml) was 
added to DCM (500ml) and the solution cooled to -20°C (acetone/dry ice bath). A 
cold solution of sodium nitrite (124.5g, 18mol) in water (200ml) was added in one 
portion with stirring. An ice-cold solution of 5% w/w H2SO4/H2O (142.5g) was 
added dropwise maintaining the temperature at < 15°C. The reaction was then 
allowed to rise to 0°C. The reaction was transferred to an ice-cold separating funnel 
and the yellow organic layer run in to an ice-cold solution of 5% w/v Na2CO3/H2O 
(11). The aqueous layer was extracted with DCM (3 x 500ml) and combined with the 
Na2CO3 layer. These were then allowed to stir until no gas evolved. The two layers 
were then separated and the aqueous layer extracted with DCM (500ml). The DCM 
extracts were combined, dried (MgSO4) and the solvent removed under reduced 
pressure. The resulting yellow oil was stored at 5°C overnight.
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The diazoacetic ester salt 
Preparation of the Vilsmaier Reagent
DMF (52.8g, 0.72mol) was cooled in an ice/salt bath under an atmosphere of argon. 
Freshly distilled thionyl chloride (53ml, 0.72mol) was added dropwise with stirring 
and the solution allowed to stir for 30 mins. The resulting colourless gel was 
evaporated to yield the Vilsmaier reagent as a white solid.
The Vilsmaier Reagent was dissolved in chloroform (400ml) and cooled in an 
ice/salt bath. The ethyl diazoacetate was added dropwise keeping the temperature 
below 5°C. The reaction was stirred at room temp for 30 mins and the solvent 
removed under reduced pressure. (Due to the potential explosion hazard this was not 
taken to complete dryness.) Ether was added to the resulting residue to give a soft 
yellow solid which was filtered under nitrogen and stored in the vacuum dessicator 
overnight.
l-Hydroxy-4-ethoxy-carbonyI-l,2,3-triazole(HOCt)
Hydroxylamine (HC1 salt, 44g, 0.63mol) was dissolved in distilled water (200ml) 
and cooled in an ice/salt bath. The pH of the solution was adjusted to 7-7.5 with 
solid Na2CO3 . The diazonium salt (140g) was added as a solid keeping the pH at 7- 
7.5 by the addition of 10% NaiCOs. The yellow product which precipitated was 
stirred for 5 mins, filtered, washed with a little ice cold water, dissolved in CHCls, 
dried (MgSO4) and filtered. Acetic acid (0.5ml) was added to this and the solution 
left to cyclise at 5°C. Once cyclisation occurred (confirmed by ] H NMR) the solvent 
was removed under reduced pressure and the resulting oil recrystallised from EtOAc 
to yield l-hydroxy-4-ethoxy-carbonyl-l,2,3-triazole as a white solid. 
Yield 21g, 21%; Mp 76-77°C (lit 77-79°C) 11 ; MS FAB m/z - 158 (MH"); HRMS 
158.0564 (MH+ requires 158.0566); CHN found C 38.27%, H 4.48%, N 26.58% 
(C5H7N303 requires C 38.22%, H 4.49%, N 26.74%); *H NMR (250MHz, CDC13 
6H/ppm) 1.33 (3H, t, J = 7.13, CH3 ), 4.34 (2H, q, J = 7.13, CH2), 8.10 (1H, s, 
aromatic CH), 13.96 (1H, br, OH); 13C {'H} NMR (63MHz, CDC13 8C/ppm) 
(63MHz, CDC13 ) 13.91 (q), 61.73 (t), 121.85 (d), 136.48 (d), 159.11 (s); FTIR 
Vmax/cm"1 (bromoform) 1140 (C-O), 1536 (aromatic), 1728 (OO), 2975 (CH), 3017 
(aromatic CH), 3155 (OH); AWnm (MeOH, e/dnvW'cuf1 ) 257 (2237).
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A.1 X-ray Crystal Data for 2-(4-pyridinyl)-l,3-thiazolidine-4-carboxylic acid 
(2.4)
Table 1. Crystal data and structure refinem
ent for Ib68sn. 
A. CRYSTAL DATA



















a = 5.7568(10) A alpha = 75.043(10) deg. 
b = 8.186(2) A beta = 75.140(9) dag. 
c = 11.172(2) A gamma - 88.661(9) deg.
491.08(15) A-3






Crystal description Colourless 
block
Crystal size 0.43 x 0.16
 x 0.12 mm
Theta range for data collection 4.24 to 70.
17 deg.
Index ranges -6<=h<=6, -
9<=k<=9, -13<=1<=13
Reflections collected 5316
Independent reflections 3400 [R(int
) = 0.0132]
Scan type omega-theta
Absorption correction Psi-scans 
(Tmin= 0.449, Tm«x=0.833)
C. SOLUTION AND REFINEMENT.
Solution
Refinement type
Program used for refinement
Hydrogen atom placement
Hydrogen atom treatment
Data / restraints / parameters
Goodness-of-fit on F"2 
Conventional R (F>4sigma(F)] 
R indices (all data) 





Largest diff. peak and hole
direct (SIR92)
Full-matrix least-squares on F"2
SHELXTL version 5
Calculated and difference map (NH3+)
Riding and rotating group (NH3+) 
3398/3/257
1.006
Rl = 0.0362 [2846 data]




2*+O.OOOOP] where P=(Fo"2"-t-2Fc'2-)/3 
0.258 and -0.258 a.A'-3
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Appendix
Table 2. Atomic coordinates ( x 10*4) and equivalent isotropic 
displacement parameters (A*2 x 10"3) for 1. O(eq) is defined 
























































































































































































































C(2 ' ) ~S ( 1 ' ) *"C( 13 ' ) 











C(50' )-C(40' )-C(13' )




































Symmetry transformations used to generate equivalent atoms:
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Appendix
Table 4. Anisotropic displacement, parameters (A'2 x 10"3) for 1. 
The anisotropic displacement factor exponent takes the form: 
-2 pi-2 [ h~2 a*-2 Ull + ... > 2 h k a* b* U12 ]





































































































































































































Table 5. Hydrogen coordinates ( x 10*4) and isotropic 





































































































































A.2 X-ray Crystal Data for 2-(3-pyridinyl)-l,3-thiazolidme-4-carboxylic acid
(2.3)













a = 9.934(2) A alpha = 90 dag.
b » 8.777(2) A beta = 95.269(14) deg.
c m 11.122(3) A gamma = 90 deg.
965.7(3) A-3










0.25 x 0.19 x 0.16 am








2328 [R(int) = 0.0919]
omega-theta
Psi-scans (Tmin= 0.335, Tmax=0.598)
Data / restraints / parameters 2326/1/259 (Pull-matrix
least-squares on F*2)
Goodness-of-fit on F"2 
Conventional R [P>4sigma(F)] 
R indices (all data) 




Rl = O.OS87 [1606 data]





calc w=l/(\s"2"(Fo*2*)+(0.0597P)*2"+O.OOOOP] where P=(Fo-2"+2Fc"2")/3
Largest diff. peak and hole 0.332 and -0.374 a.A*-3
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Appendix
Table 2. Ato»ic coordinates ( x 10*4) and equivalent isotropic
displacement parameters (A*2 x 10*3) for 1. O(eq) is defined








































































































































































































































C(40' )-C(30' )-C( 13' )
C(50' )-C(40' )-C(30' )
C(40' )-C(50' )-C(60- )



































sysn»etry transformations used to generate equivalent atoms:
14
Appendix
Table 4. Anisotropic displacement parameters (A*2 x 10-3) for 1. 
The anisotropic displacement factor exponent takes toe form: 
-2 pi*2 [ h*2 a*"2 Ull  +  ... + 2 h k a* b* O12 ]





































































































































































































Table 5. Hydrogen coordinates ( x 10*4) and isotropic 
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September 1997, various speaker
6th Solid Phase Synthesis and Combinatorial Libraries Symposium, York, September 
1999, various speakers
SCI One Day Syposium, Understanding Protein Protein Interactions, London, June
1998. various speakers
RSC Conference, Biological Challenges in Synthetic Organic Chemistry, St. 
Andrews University, July 1999, various speakers
Current Awareness in Organic Chemistry, (sponsored by Zeneca Grangemouth), 
University of Edinburgh, May 1997, 1998, 1999, various speakers
Edinburgh Centre for Protein Technology lectures, University of Edinburgh, 1996 -
1999. various speakers
Walker Memorial Lectures, University of Edinburgh, 1996 - 1999, various speakers
RSC Conference, Medicinal Chemistry, Edinburgh, September 1998, various 
speakers
Centre for Teaching and Learning Assessment, Demonstrating Course, University of 
Edinburgh, October 1996
